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BACKGROUND: Research into the therapeutic potential of α-calcitonin 
gene–related peptide (α-CGRP) has been limited because of its peptide 
nature and short half-life. Here, we evaluate whether a novel potent and 
long-lasting (t½ ≥7 hours) acylated α-CGRP analogue (αAnalogue) could 
alleviate and reverse cardiovascular disease in 2 distinct murine models of 
hypertension and heart failure in vivo.
METHODS: The ability of the αAnalogue to act selectively via the CGRP 
pathway was shown in skin by using a CGRP receptor antagonist. 
The effect of the αAnalogue on angiotensin II–induced hypertension 
was investigated over 14 days. Blood pressure was measured by 
radiotelemetry. The ability of the αAnalogue to modulate heart failure 
was studied in an abdominal aortic constriction model of murine cardiac 
hypertrophy and heart failure over 5 weeks. Extensive ex vivo analysis was 
performed via RNA analysis, Western blot, and histology.
RESULTS: The angiotensin II–induced hypertension was attenuated by 
cotreatment with the αAnalogue (50 nmol·kg–1·d–1, SC, at a dose selected 
for lack of long-term hypotensive effects at baseline). The αAnalogue 
protected against vascular, renal, and cardiac dysfunction, characterized 
by reduced hypertrophy and biomarkers of fibrosis, remodeling, 
inflammation, and oxidative stress. In a separate study, the αAnalogue 
reversed angiotensin II–induced hypertension and associated vascular and 
cardiac damage. The αAnalogue was effective over 5 weeks in a murine 
model of cardiac hypertrophy and heart failure. It preserved heart function, 
assessed by echocardiography, while protecting against adverse cardiac 
remodeling and apoptosis. Moreover, treatment with the αAnalogue was 
well tolerated with neither signs of desensitization nor behavioral changes.
CONCLUSIONS: These findings, in 2 distinct models, provide the 
first evidence for the therapeutic potential of a stabilized αAnalogue, 
by mediating (1) antihypertensive effects, (2) attenuating cardiac 
remodeling, and (3) increasing angiogenesis and cell survival to 
protect against and limit damage associated with the progression of 
cardiovascular diseases. This indicates the therapeutic potential of the 
CGRP pathway and the possibility that this injectable CGRP analogue 
may be effective in cardiac disease.
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Calcitonin gene-related peptide (CGRP) is a mem-ber of the calcitonin family of peptides. CGRP is primarily localized to sensory nerves, although 
nonneuronal sources are reported.1 The major CGRP 
receptor is formed by the coexpression of calcitonin 
receptor-like receptor (CLR) with receptor activity–mod-
ifying protein-1 (RAMP1).1 These receptors are found 
throughout the cardiovascular system, specifically in 
the media, intima, and endothelial layer of blood ves-
sels. Although CGRP is established as a potent vaso-
dilator, there is little evidence that sufficient endoge-
nous CGRP is released to influence physiological blood 
pressure regulation, although CGRP-containing nerves 
surround all cardiovascular tissues. Several CGRP recep-
tor antagonists and antibodies developed as migraine 
therapies have minimal effect on blood pressure in 
healthy individuals.1,2 Evidence that CGRP plays a role 
in cardiovascular protection arises from acute studies 
where CGRP has been administered in rodent models 
of hypertension,3,4 using spontaneously hypertensive 
rats5,6 and α-CGRP–specific knockout (KO) mice.7 The 
beneficial effects of the native CGRP peptide have also 
been observed when administered for up to 24 hours 
to patients with congestive heart failure with no evi-
dence of tolerance.8,9
Although systemic endogenous CGRP levels are 
raised in some conditions such as pregnancy, it has 
proven difficult to raise endogenous CGRP levels to 
provide cardiovascular benefit. There is little evidence 
that stimulation of the major sensory nerve-localized 
transient receptor potential (TRP) channels (TRPV1 
or TRPA1) releases CGRP to play a primary protective 
endogenous role in hypertension.10,11 This is despite 
knowledge that activation of TRP channels expressed 
on sensory nerves induces CGRP-dependent vasodila-
tion in peripheral tissues such as skin.12 Of note, TRPA1 
activation using nitroxyl13 mediates inotropic effects in 
the failing heart,14 but the importance of CGRP is de-
bated.15 Some CGRP/calcitonin KO mouse strains pos-
sess a raised blood pressure at baseline, indicating a 
potential role of endogenous CGRP.1,16 We have shown 
that α-CGRP–specific KO mice have normal baseline 
blood pressure but enhanced hypertension following 
angiotensin II (AngII) infusion for up to 28 days, in com-
parison with wild-type mice.7 This was associated with 
aortic hypertrophy and endothelial dysfunction ob-
served as loss of endothelial nitric oxide synthase and 
evidence of oxidative stress.7
This and related knowledge, together with the un-
derstanding that global human RAMP1 transgenic mice 
are protected from hypertension,17 led us to hypoth-
esize that a stabilized α-CGRP agonist with the ability 
to remain active over prolonged periods would elicit 
cardioprotective properties. This first α-CGRP analogue 
(αAnalogue) is acylated with an albumin-binding fatty 
acid moiety that allows reversible albumin binding (pat-
ent WO 2011/051312 A1).18,19 It has similar pharmaco-
logical properties to the native CGRP peptide, but ex-
hibits prolonged action and improved pharmacokinetic 
properties with a half-life of >7 hours that benefited a 
model of type 2 diabetes mellitus.18,19 The current study 
demonstrates that the stabilized αAnalogue18 protects 
against the development of AngII-induced hyperten-
sion and abdominal aortic constriction (AAC)–induced 
cardiac hypertrophy and heart failure in mice for sev-
eral weeks. We have determined mechanisms by which 
this αAnalogue can reverse vascular, renal, and cardiac 
damage. To our knowledge, this is the first detailed 
study using an α-CGRP agonist that has improved sta-
bility over the native peptide and illustrates the poten-
tial of the CGRP pathway as a therapeutic target and in-
jectable stabilized CGRP agonists as therapeutic agents.
METHODS
A detailed Methods is provided in the online-only Data 
Supplement.
Animals
Experiments complied with ARRIVE (Animal Research: 
Reporting In vivo Experiments) guidelines, in accordance with 
the UK Home Office Animals (Scientific Procedures) Act, 1986 
and approved by the local Animal Care and Ethics Committee. 
Clinical Perspective
What Is New?
• We have used a novel injectable stabilized 
α-calcitonin gene–related peptide (CGRP) agonist, 
the first to our knowledge, to analyze the effect on 
cardiovascular disease in 2 distinct murine models.
• We show that the CGRP agonist is well tolerated 
and selective in the vasculature.
• The CGRP agonist prevented the onset of and lim-
ited angiotensin II–induced hypertension.
• The CGRP agonist also protected against heart 
failure in the abdominal aortic constriction model, 
suggesting that this α-CGRP analogue is beneficial 
in cardiovascular disease.
What Are the Clinical Implications?
• These preclinical data show that activating the 
protective CGRP pathway, using selective stabi-
lized agonists, constitutes a novel therapeutic 
application.
• The results are a stimulus to further develop ago-
nists, including those that are orally active.
• The results highlight the potential development 
of this injectable stabilized CGRP agonist (α-CGRP 
analogue) for the treatment of cardiac dysfunction 
(eg, in advanced heart failure).
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Male mice, CD1 or C57BL/6J (12–18 weeks of age; Charles 
River) were used.
AngII Murine Hypertension Model
Mice were infused with AngII (1.1 mg·kg–1·d–1) or saline 
(control) continuously for 14 days via osmotic mini pumps, 
as previously.7 Mice were treated daily with αAnalogue (50 
nmol·kg–1·d–1, SC) or vehicle (0.219 mol/L mannitol, 5% 
hydroxypropyl-β-cyclodextrin, 1.6% ammonium acetate at 
pH6.5) for 14 days or at 7 days onward for therapeutic dosing.
Cardiac Hypertrophy Murine Model
Mice were surgically subjected to pressure overload–induced 
cardiac hypertrophy and heart failure20 for 5 weeks and 
treated daily with αAnalogue (50 nmol·kg–1·d–1, SC) or vehicle.
Measurement of Cutaneous Blood Flow
Blood flow was assessed in the ear, leg, or paw using the 
Full-field Laser Perfusion Imager (Moor Instruments) on anes-
thetized mice.12 To investigate the local effects of αAnalogue, 
mice were pretreated with the CGRP antagonist BIBN4096 
(0.3 mg/kg, IV) or control (neutralized saline) followed by 
αAnalogue injection (100 pmol daily, ipsilateral ear) or vehicle 
(contralateral ear). In separate experiments, blood flow in the 
periphery was measured following systemic treatment of the 
αAnalogue.
Measurement of Blood Pressure
Blood pressure, heart rate, and activity were measured using 
a radiotelemetry (PA-C10, DSI), as previously described10–12 in 
AngII-infused C57BL/6J mice. For the characterization of the 
systemic dose of αAnalogue, blood pressure was measured 
by tail-cuff plethysmography (CODA 8, Kent Scientific) in con-
scious mice.7,10 Following AAC-induced cardiac hypertrophy, 
blood pressure was measured via carotid artery in anesthe-
tized mice.
Echocardiography
In vivo cardiac function was assessed using a Vevo 2100 
Imaging System with a 40-MHz linear probe (Visualsonics).20 
Data analysis was performed with Vevo 2100 software v.1.2.1 
(Visualsonics).
Light Aversion Assay
Light aversion (10 minutes, 1000 lux) was determined at base-
line and 2 hours following injection of αAnalogue, vehicle, or 
Figure 1. α-CGRP analogue (αAnalogue) increases vascular blood flow via CGRP receptors.  
Blood flow monitored using Full-field Laser Perfusion Imager in the ear vasculature of mice pretreated with control (saline) or 
CGRP receptor antagonist BIBN4096 (0.3 mg/kg, IV) at baseline and following intradermal injection of αAnalogue (100 pmol, 
daily) or vehicle (Veh) (15 µL, n=6). A, Blood flow responses expressed as % change from baseline. B, Representative Full-field 
Laser Perfusion Imager pictures alongside gray/black photo showing blood flow at baseline and 15 minutes after treatment. 
C, Blood flow assessed by area under the curve (AUC) for 30 minutes following vehicle or αAnalogue administration (n=6). 
Data showed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001 versus vehicle-treated; #P<0.05, ##P<0.01, ###P<0.001 for 
αAnalogue treated (A, repeated-measures 2-way ANOVA + Bonferroni post hoc test; C, 2-way ANOVA + Bonferroni post hoc 
test). α-CGRP indicates α-calcitonin gene–related peptide.
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Figure 2. Daily systemic treatment with α-CGRP analogue (αAnalogue) protects against angiotensin II (AngII)–
induced hypertension and vascular damage.  
Mice were infused with AngII (A, 1.1 mg·kg–1·d-–1) or control (S, saline) for 14 days and treated daily with vehicle (V) or αAnalogue 
(50 nmol/kg, SC). A, Systolic blood pressure was measured by radiotelemetry. Results expressed as 6-hour average. (Continued )
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positive control glyceryl trinitrate (320 nmol/kg, IV). See the 
online-only Data Supplement.
Glucose Tolerance Test 
Mice were fasted for 6 hours and treated with glucose (1 g/
kg, IP). Blood glucose level was determined at baseline and 
stated time points using a One Touch Vita glucose meter 
(Lifescan).
RNA Preparation and Real-Time 
Quantitative Polymerase Chain  
Reaction 
Total RNA was extracted using the Qiagen RNeasy Microarray 
Mini Kit (Qiagen), followed by reverse transcription into cDNA 
(Applied Biosystems, Life technologies Ltd). Quantitative poly-
merase chain reaction was performed with a SYBR-green–
based polymerase chain reaction mix (Sensi-Mix, SYBR-green 
No ROX; Bioline). Primer details are listed in online-only Data 
Supplement Table I.
Western Blotting
Western blot analysis was performed in aorta, mesentery, 
heart, and kidney as previously described.7 Antibody details 
are listed in the online-only Data Supplement.
Quantification of Noradrenaline 
and Cytokines Using Enzyme-Linked 
Immunosorbent Assay
After 14 days of AngII or saline infusion, plasma and kidney 
samples were collected for determination of noradrenaline 
and inflammatory cytokines (interleukin-6, tumor necrosis 
factor-α) by using standard enzyme-linked immunosorbent 
assay as described in the online-only Data Supplement.
Histology
Aorta, heart, and kidney tissues were fixed in 4% para-
formaldehyde, as previously described.7 Staining proto-
col and antibody details are listed in the online-only Data 
Supplement.
Statistical Analysis
Results are expressed as mean±SEM. Statistical analysis was 
performed using an unpaired 2-tailed Student t test, 1-way 
or repeated-measures 2-way ANOVA followed by Bonferroni 
post hoc test. P<0.05 was considered to represent a signifi-
cant difference.
RESULTS
Effects of Local Administration of the 
αAnalogue on Vascular Blood Flow
Initial studies determined the ability of the αAnalogue 
to increase blood flow via the CGRP receptor (CLR/
RAMP1) pathway. Intradermal administration of the 
αAnalogue increased blood flow in a dose-dependent 
manner in the skin of anesthetized naive mice as deter-
mined by laser perfusion imaging (Figure 1A and 1B, 
online-only Data Supplement Figure I). This effect was 
abolished by the selective nonpeptide CGRP receptor 
antagonist BIBN4096 (Figure 1A through 1C).
Systemic Treatment With the αAnalogue 
Protects Against Hypertension
Systemic injection of the αAnalogue (10–100 nmol/
kg, SC) induced a dose-dependent decrease in blood 
pressure at 1 to 6 hours, with significance observed at 
100 nmol/kg in comparison with vehicle treatment, as-
sessed by tail-cuff in naive mice (online-only Data Sup-
plement Figure II). A 50 nmol/kg dose was chosen for 
further studies, because the hypotensive response had 
recovered by 24 hours in all mice. It is important to note 
that the blood pressure effects of the αAnalogue (50 
nmol/kg, SC) were not significantly different from ve-
hicle-treated mice (Figure 2A, online-only Data Supple-
ment Figure III). All mice demonstrated normal diurnal 
variations in cardiovascular hemodynamics at baseline, 
followed by a hypertensive phenotype post–AngII infu-
sion (Figure 2, online-only Data Supplement Figure III). 
Daily systemic treatment with the αAnalogue through-
out the 14 days markedly blunted AngII-induced hy-
pertension (Figure  2A, online-only Data Supplement 
Figure III). No significant change in heart rate or activ-
ity was observed among treatment groups (online-only 
Data Supplement Figure III).
In the AngII-infused mice, treatment with the 
αAnalogue leads to a reproducible reduction in blood 
pressure, with a similar reduction observed at day 1 to 
day 14 of treatment (online-only Data Supplement Fig-
ure IV), although there was a reduced hypotensive re-
sponse to the αAnalogue on the last day. However, the 
protective activity was clearly maintained, with marked 
reduction in vascular remodeling and oxidative stress 
Figure 2 Continued. Mice experience a 12/12 hour light/dark cycle, with the dark cycle shown in the gray striped area. 
Arrow represents the start of daily treatment. B, Protein expression of total eNOS in aorta (n=4–5). C, Representative im-
ages of Masson trichrome-stained aortic sections. D, Quantification of smooth muscle wall width (n=4–5; scale bars, 100 
µm). Protein expression of NADPH oxidase-2 (NOX-2) (E), heme oxygenase-1 (HO-1) (F), nitrotyrosine in aorta (n=4–6) (G). 
H, Protein expression of nitrotyrosine in mesenteric vessels (n=6–7). Results shown as mean±SEM. *P<0.05, **P<0.01, 
***P<0.001 versus vehicle-treated saline-infused; #P<0.05, ##P<0.01, ###P<0.001 for αAnalogue-treated AngII-infused 
versus vehicle-treated AngII-infused (A, repeated-measures 2-way ANOVA + Bonferroni post hoc test; B through H, 2-way 
ANOVA + Bonferroni post hoc test). α-CGRP indicates α-calcitonin gene–related peptide; and eNOS, endothelial nitric 
oxide synthase.
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(Figure  2). AngII infusion increased water consump-
tion from day 3, consistent with previous findings,21 
and this was reduced by the αAnalogue treatment 
throughout the time course (online-only Data Supple-
ment Figure VA and VB). Typically, AngII reduced body 
weight, which was absent in αAnalogue-treated mice 
(online-only Data Supplement Figure VC). Food intake 
was not affected in any treatment groups (online-only 
Data Supplement Figure VD).
Systemic Treatment With the αAnalogue 
Does Not Affect Normal Behavioral 
Responses or Glucose Homeostasis
One of the limiting factors in the potential use of 
CGRP agonists therapeutically is that they may cause 
indications relevant to migraine, flushing, or meta-
bolic changes.1 We therefore examined its effects on 
activity and core body temperature by radiotelemetry, 
behavioral responses using a light aversion assay, and 
signs of flushing by assessing peripheral blood flow. 
Treatment with the αAnalogue (50 nmol/kg, SC) had 
no effect on activity (online-only Data Supplement Fig-
ure IIID) or light avoidance in comparison with base-
line (online-only Data Supplement Figure VI), unlike 
glyceryl trinitrate, an established inducer of migraine 
symptoms. Neither acute nor chronic systemic treat-
ment of the αAnalogue had a significant effect on 
skin blood flow (online-only Data Supplement Figure 
VII). We found no significant change in core body tem-
perature (online-only Data Supplement Figure VIII) or 
in glucose homeostasis (online-only Data Supplement 
Figure IX) with the αAnalogue treatment in compari-
son with vehicle.
αAnalogue Protects Against AngII-
Induced Vascular Changes in the Aorta 
and Mesentery
AngII infusion caused endothelial dysfunction, re-
vealed by a significant decrease in endothelial nitric 
oxide synthase expression and vascular hypertrophy, 
Figure 3. α-CGRP analogue (αAnalogue) protects against angiotensin II (AngII)–induced cardiac hypertrophy  
and fibrosis.  
Mice were treated as in Figure 2 (AngII, A; Saline, S). A, Left ventricle weight normalized to tibia length ratio (mg/mm). B, 
Protein expression of α-smooth muscle actin (α-SMA) in heart (n=5). mRNA expression measured by real-time quantitative 
polymerase chain reaction for transforming growth factor-β1 (TGF-β1) (C), fibronectin (D), collagen type 1 α1 (COL1A1) (E), 
collagen type 1 α2 (COL1A2) (F), collagen type 3 α1 (COL3A1) (G), collagen type 4 α1 (COL4A1) (H), atrial natriuretic peptide 
(ANP) (I), brain natriuretic peptide (BNP) (J), matrix metalloproteinase-2 (MMP-2) (K), and sarcoplasmic reticulum Ca2+ ATPase-2 
(SERCA-2) (L) in heart (n=5–11). Results expressed as copy numbers per microliter normalized to hypoxanthine-guanine phos-
phoribosyltransferase, B2M and β-actin, and showed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001 versus vehicle-treated 
saline-infused; #P<0.05, ##P<0.01, ###P<0.001 versus vehicle-treated AngII-infused (2-way ANOVA + Bonferroni post hoc 
test). α-CGRP indicates α-calcitonin gene–related peptide.
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with increased aortic wall thickness. These were 
not observed in mice treated with the αAnalogue 
(Figure  2B through 2D). AngII upregulated NADPH 
oxidase-2 (NOX-2) expression, accompanied by in-
creased vascular aortic oxidative stress, as reflected 
by an increase in the stress-response protein heme 
oxygenase-1 (HO-1) and nitration of protein tyrosine 
residues, an indication of peroxynitrite formation in 
vehicle-treated AngII-infused mice. These responses 
were attenuated by the αAnalogue (Figure 2E through 
2G). Although we observed no changes in endothelial 
nitric oxide synthase expression following AngII infu-
sion in mesenteric vessels (online-only Data Supple-
ment Figure X), there was a marked increase in nitro-
sative stress, which was blocked by the αAnalogue 
(Figure 2H).
Figure 4. Daily systemic treatment with α-CGRP analogue (αAnalogue) protects against angiotensin II (AngII)–
induced cardiac inflammation and oxidative stress. 
Mice were treated as in Figure 2 (AngII, A; Saline, S). mRNA expression measured by real-time quantitative polymerase chain 
reaction (n=5–11) for RANTES (A) and glutathione peroxidase-1 (GPX-1) (n=6–11) (B). C, Protein expression of GPX-1 in heart 
(n=5). mRNA expression for hypoxia-inducible factor-1 (HIF-1α) (D), heme oxygenase-1 (HO-1) (E), and NADPH dehydroge-
nase quinone-1 (NQO1) (n=5–11) (F). Results expressed as copy numbers per microliter normalized to hypoxanthine-guanine 
phosphoribosyltransferase, B2M and β-actin, and showed as mean±SEM. G, Protein expression of nitrotyrosine (n=5) in heart 
(n=6–7). *P<0.05, **P<0.01, ***P<0.001 versus vehicle-treated saline-infused; #P<0.05, ##P<0.01, ###P<0.001 versus vehicle-
treated AngII-infused (2-way ANOVA + Bonferroni post hoc test). α-CGRP indicates α-calcitonin gene–related peptide.
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Figure 5. Daily systemic treatment with α-CGRP analogue (αAnalogue) protects against angiotensin II (AngII)–
induced renal fibrosis, dysfunction, and inflammation.  
Mice were treated as in Figure 2 (AngII, A; Saline, S). mRNA (A) and protein expression of α-SMA (B) in kidney. mRNA (Continued )
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αAnalogue Treatment Protects Against 
AngII-Induced Cardiac Remodeling, 
Fibrosis, and Oxidative Stress
AngII-induced cardiac hypertrophy was reduced by the 
αAnalogue (Figure 3A, online-only Data Supplement 
Table II). Hearts of vehicle-treated but not αAnalogue-
treated AngII-infused mice showed increased protein 
expression of α-smooth muscle actin and mRNA ex-
pression of several cardiac stress markers, including 
transforming growth factor-β1, a major driver of car-
diac fibrosis, extracellular matrix remodeling markers 
such as connective tissue growth factor, fibronectin, 
collagen type 1, 3, and 4, and natriuretic peptides such 
as atrial natriuretic peptide and brain natriuretic pep-
tide (Figure 3B through 3J, online-only Data Supple-
ment Table III). Transforming growth factor-β1 induces 
matrix metalloproteinase-2 in fibroblasts contribut-
ing to cardiac remodeling.22 Daily treatment with the 
αAnalogue protected against AngII-induced changes 
in matrix metalloproteinase-2 and the corresponding 
tissue inhibitor of metalloproteinase-2 mRNA expres-
sion in the hearts (Figure  3K, online-only Data Sup-
plement Table III). The cardiac muscle–specific sarco-
plasmic reticulum Ca2+ ATPase-2 is important in Ca2+ 
handling, and its expression decreases under patho-
logical conditions, leading to contractile dysfunction.23 
The αAnalogue protected against AngII-induced de-
crease in sarcoplasmic reticulum Ca2+ ATPase-2 mRNA 
expression (Figure 3L).
The αAnalogue protected against AngII-induced in-
flammation, as shown by reduced mRNA expression 
of the nuclear factor kappa B cells and the chemo-
kine RANTES (Figure 4A, online-only Data Supplement 
Table III). Treatment with the αAnalogue caused no 
change in the apoptosis regulator B-cell lymphoma-2 
(Bcl-2) but resulted in a significant reduction in apop-
totic markers such as p53 in AngII-infused hearts 
(online-only Data Supplement Table III). We next de-
termined the effects of the αAnalogue on oxidative 
stress. AngII-induced increase in the antioxidant en-
zyme glutathione peroxidase-1 expression was absent 
in αAnalogue-treated groups (Figure 4B and 4C). An 
increase in hypoxia-inducible factor 1α was attenu-
ated by αAnalogue treatment (Figure  4D). AngII-in-
duced changes in the mRNA expression of HO-1 and 
the phase II detoxifying enzymes NADPH dehydroge-
nase quinone-1 were absent by daily treatment with 
the αAnalogue (Figure 4E and 4F). Cardiac nitrosative 
stress was absent by the αAnalogue treatment in An-
gII-infused mice (Figure 4G). Collectively, these results 
show a marked protective effect on the proinflamma-
tory and oxidative pathways associated with AngII-
induced cardiovascular disease.
αAnalogue Protects Against AngII-
Induced Renal Fibrosis and Injury
AngII infusion caused renal fibrosis, indicated by up-
regulation of α-smooth muscle actin expression, in-
creased transforming growth factor-β1 and collagen 
mRNA expression, which were absent in mice cotreat-
ed with the αAnalogue (Figure 5A through 5D). The 
kidneys of AngII-infused mice exhibited renal damage, 
with increased mRNA expression of cystatin C and 
neutrophil gelatinase-associated lipocalin, plasma and 
renal creatinine levels, and mesangial matrix expan-
sion in the glomeruli, which were all absent in mice 
treated with the αAnalogue (Figure  5E through 5H, 
online-only Data Supplement Figure XI). AngII infu-
sion resulted in renal inflammation, highlighted by in-
creased interleukin-6 and tumor necrosis factor-α con-
centrations, which were abolished by the αAnalogue 
(Figure  5I and 5J). There was a significant increase 
in localized sympathetic nerve activity, shown by in-
creased noradrenaline content in AngII-infused kidney 
but not plasma, which was blocked by αAnalogue 
treatment (Figure 5K, online-only Data Supplemental 
Figure XII). The decreased noradrenaline levels in the 
kidney provides evidence that CGRP was able to at-
tenuate the sympathetic activity. Downregulation of 
renal klotho expression can aggravate AngII-induced 
renal damage.24 Here, the αAnalogue protects against 
this downregulation (Figure 5L).
αAnalogue Protects Against AngII-Induced 
Upregulation of CGRP Receptor RAMP1
RAMP1 determines the CGRP receptor phenotype when 
associated with CLR, and CGRP receptors are upregu-
lated in cardiovascular disease models.1 We observed 
a significant increase in CGRP receptor RAMP1 protein 
expression in the aorta, mesentery, and heart of vehi-
cle-treated AngII-infused mice but not the αAnalogue 
Figure 5 Continued. expression of TGF-β1 (C), collagen type 1a1 (COL1A1) (D), cystatin C (E), and neutrophil gelatinase-asso-
ciated lipocalin (NGAL) (F) in kidney. Creatinine levels in kidney (G) and plasma (H) (n=6–8). IL-6 (I), TNF-α (J), and noradrena-
line (NA) (K) levels in kidney (n=6–9). L, Protein expression of klotho in kidney. mRNA expression measured by real-time quan-
titative polymerase chain reaction (n=6–8), expressed as copy numbers per microliter normalized to hypoxanthine-guanine 
phosphoribosyltransferase, B2M, and β-actin. Results shown as mean±SEM. *P<0.05, **P<0.01, ***P<0.001 versus vehicle-
treated saline-infused; #P<0.05, ##P<0.01 versus vehicle-treated AngII-infused (2-way ANOVA + Bonferroni post hoc test). 
α-CGRP indicates α-calcitonin gene–related peptide; IL-6, interleukin 6; α-SMA; α-smooth muscle actin; TGF-β1; transforming 
growth factor-β1; and TNF-α, tumor necrosis factor-α.
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(Figure 6). There was no significant change in CLR ex-
pression observed in different tissues, regardless of treat-
ment (Figure 6). We found no change in endothelin-1 
expression in heart or aorta treated with vehicle or the 
αAnalogue (online-only Data Supplement Figure XIII).
αAnalogue Limits AngII-Induced 
Hypertension and Associated Cardiac 
Remodeling
To determine whether the αAnalogue influences estab-
lished hypertension, we assessed its effects by starting 
treatment at day 7 of AngII infusion. Treatment with 
the αAnalogue attenuated AngII-induced hypertension 
(Figure  7A, online-only Data Supplement Figure XIV). 
We observed a significant decrease in Akt and osteo-
pontin, remodeling, and fibrotic markers (transforming 
growth factor-β1, connective tissue growth factor, α-
smooth muscle actin, collagen type 1 and 3), NOX-2, 
and markers of oxidative stress (HO-1, NADPH dehydro-
genase quinone-1) in aorta (online-only Data Supple-
ment Table IV). Accordingly, a substantial decrease in 
cardiac hypertrophy was found, with a significant re-
duction in left ventricular weight:tibia length ratio (Fig-
ure  7B, online-only Data Supplement Table V) and in 
cardiac fibrosis, remodeling, and inflammation, shown 
by a significant reduction in collagen type 3, atrial na-
triuretic peptide, and NOX-2 mRNA expression (online-
only Data Supplement Table VI). It is notable that the 
αAnalogue reduced AngII-mediated increase in car-
diomyocyte size and collagen deposition, revealed by 
wheat germ agglutinin and Picrosirius Red staining, re-
spectively (Figure 7C and 7D). Cardiac nitrosative stress 
was reversed by the αAnalogue in hypertensive mice 
(Figure 7E).
αAnalogue Protects Against AAC-Induced 
Cardiac Hypertrophy and Heart Failure
To investigate the cardioprotective effect of CGRP in 
heart failure, mice were subjected to sham or AAC-
induced cardiac hypertrophy and heart failure for 5 
weeks. Quantification of in vivo cardiac function re-
vealed that ejection fraction was better preserved in 
αAnalogue-treated AAC mice, with a reduction in sep-
tum wall thickness as shown by echocardiography (Fig-
ure 8A and 8B, online-only Data Supplement Figure XV, 
and online-only Data Supplement Table VII). Chronic 
treatment with the αAnalogue for 5 weeks was well 
tolerated, with no significant change in body weight, 
food and water intake, light avoidance, or blood pres-
sure (online-only Data Supplement Figures XVI and 
XVII). αAnalogue-treated mice consistently developed 
less cardiac hypertrophy and fibrosis after AAC than ve-
hicle-treated groups (Figure 8C, 8E through 8H, online-
Figure 6. Effects of daily systemic treatment with α-
CGRP analogue (αAnalogue) on CGRP receptor expres-
sion in angiotensin II (AngII)–induced hypertension.  
Mice were treated as in Figure 2 (AngII, A; saline, S, V, 
vehicle; α-CGRP analogue; C). Protein expression of calcito-
nin receptor-like receptor (CLR) (A) and receptor-associated 
membrane protein-1 (RAMP1) (B) in aorta (n=6). Protein 
expression of CLR (C) and RAMP1 (D) in mesenteric vessels 
(n=6). Protein expression of CLR (E) and RAMP1 (F) in heart 
(n=6–7). Protein expression of CLR (G) and RAMP1 (H) in 
kidney (n=5–6). Results showed as mean±SEM.*P<0.05, 
***P<0.001 versus vehicle-treated saline-infused; #P<0.05, 
###P<0.001 versus vehicle-treated AngII-infused (2-way 
ANOVA + Bonferroni post hoc test). α-CGRP indicates α-
calcitonin gene–related peptide.
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Figure 7. α-CGRP analogue (αAnalogue) limits angiotensin II (AngII)–induced hypertension. 
Mice were infused with AngII (1.1 mg·kg–1·d–1 for 14 days) and treated daily with vehicle or αAnalogue (50 nmol/kg, SC) at 
day 7 to 14 of infusion (n=4). A, Systolic blood pressure was measured by radiotelemetry. Results expressed as 6-hour average. 
Mice experience a 12/12 hour light/dark cycle, with the dark cycle shown in the gray striped area. Arrow represents the start 
of daily treatment. B, Left ventricle weight normalized to tibia length ratio (mg/mm). Representative heart sections (Top) and 
analysis (Bottom) showing cardiac hypertrophy by cardiomyocyte borders outlined using wheat germ agglutinin (scale (Continued )
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only Data Supplement Table VIII, and online-only Data 
Supplement Figure XVIII). Insufficient angiogenesis is 
known as a driver of heart failure,20 and left ventricular 
heart sections subjected to AAC showed reduced capil-
lary density that was reversed by αAnalogue treatment 
(Figure 8I and 8J). Quantitative immunoblotting showed 
that phosphorylated p38 mitogen-activated protein ki-
nase levels were significantly increased in αAnalogue-
treated AAC hearts (online-only Data Supplement Fig-
ure XIX). Mice subjected to AAC showed an increase in 
cardiac inflammation, oxidative, nitrosative stress, and 
apoptosis in vehicle-treated but not αAnalogue-treated 
groups (Figure 8K through 8N, online-only Data Supple-
ment Figure XVIII).
DISCUSSION
CGRP is one of the most potent microvascular dilators 
known, and its protective properties are well established 
in vitro. However, it has been difficult to harness this in-
formation in drug discovery projects involving the cardio-
vascular system to date, primarily because of the instabil-
ity of the peptide. This study presents novel mechanistic 
evidence that chronic systemic treatment with an in-
jected stabilized α-CGRP agonist is effective in the onset 
and ongoing AngII-induced hypertension and AAC-in-
duced cardiac hypertrophy and heart failure in vivo. The 
αAnalogue, which possesses a considerably longer half-
life than the native CGRP peptide (>7 hours in compari-
son with <30 minutes) is well tolerated. Specifically, the 
agonist did not lower systemic blood pressure in naive 
mouse, but exerted beneficial protective effects at the 
vascular, renal, and cardiac levels by alleviating fibrosis, 
remodeling, inflammation, oxidative stress, apoptosis, 
and preserving overall function in 2 distinct cardiovas-
cular disease models. Our results are consistent with the 
concept that the CGRP receptor can be an influential 
regulatory component in cardiovascular disease and that 
CGRP agonists have potential therapeutic benefits.
The αAnalogue acted as a selective CGRP agonist via 
the CGRP receptor to mediate vasodilatation. Because 
the αAnalogue is not orally active, a systemic injectable 
dose that elicited an initial decrease in blood pressure 
with full recovery by 24 hours was chosen. This allowed 
baseline blood pressure to be maintained over the 2- to 
5-week protocols in the control/sham mice. Although 
systemic CGRP infusion previously led to flushing in 
humans,25 we found no undesirable side effects at the 
selected dose.
Although α-CGRP–specific KO mice have normal 
basal cardiovascular hemodynamics, they exhibit an 
enhanced hypertensive phenotype in AngII-induced 
hypertension.7 Indeed, acute injection of the native 
CGRP peptide was beneficial in hypertensive rats26 but 
effects were short lasting (<10 minutes) because of its 
short half-life.27 In contrast, CGRP infusion for 6 days 
had beneficial effects in hypertensive rats.3 To build 
on this and elucidate the mechanisms, we show that 
the αAnalogue protects against AngII-induced increase 
in blood pressure for 2 weeks. We tested for poten-
tial desensitization by the daily administration of the 
αAnalogue in naive mice and found a reproducible hy-
potensive effect, with no signs of downregulation of 
the CGRP pathway in the vasculature. However, there 
was a reduced effect on hypertension at the 14-day 
time point, leading us to investigate for other mark-
ers of disease. AngII-induced hypertension is associ-
ated with weight loss and increased water intake, in 
addition to hypertension. These were reversed by the 
αAnalogue throughout. Of interest, blocking the CGRP 
pathway with antagonists/antibodies against CGRP and 
its receptor (currently in clinical trials for prevention of 
migraine2) may interfere with this protective pathway 
and thereby increase cardiovascular risk. However, in 
the limited clinical studies performed to date, no evi-
dence has been found. It is possible that endogenous 
levels of CGRP do not reach sufficient levels in humans 
to mediate protective effects. To our knowledge, this is 
the first in-depth study in cardiovascular models with a 
long-acting CGRP agonist where there has been a sus-
tained benefit in protective cardiovascular effects.
AngII-induced vascular dysfunction and remodel-
ing were reversed by the αAnalogue, in keeping with 
reports that CGRP inhibits smooth muscle cell prolif-
eration by increasing cAMP or inhibiting the ERK1/2 
signaling cascade.28 CGRP has direct anti-inflammatory 
and antioxidant effects in endothelial progenitor cells.29 
Accordingly, the αAnalogue reduced the AngII-induced 
increase in the endogenous source of ROS30 NOX-2, ox-
idative stress-associated proteins, and nitrosative stress 
in hypertensive aorta, which was consistent with less 
nitrosative stress in the hypertensive mesenteric vessels. 
There was no change in vascular endothelial dysfunc-
tion in resistance vessels, complementing our previous 
findings.7
CGRP receptors are upregulated in cardiovascular 
disease,1 with evidence of a pressure-dependent regu-
lation.12 This may amplify responses to CGRP, especially 
in hypertension.7,17 Accordingly, RAMP1 expression was 
increased in hypertensive resistance and conduit vessels. 
The αAnalogue reduced this effect such that RAMP1 
returned to normal expression levels as the cardiovas-
Figure 7 Continued. bars, 20 µm) (C) and cardiac fibrosis by Picrosirius Red staining (scale bars, 200 µm) (D). E, Protein 
expression of nitrotyrosine in heart. Results showed as mean±SEM.*P<0.05, **P<0.01, ***P<0.001 versus vehicle-treated (A, 
repeated-measures 2-way ANOVA + Bonferroni post hoc test; B through E, 2-way ANOVA + Bonferroni post hoc test). α-CGRP 
indicates α-calcitonin gene–related peptide.
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Figure 8. α-CGRP analogue (αAnalogue) preserves heart function post–AAC-induced cardiac hypertrophy  
and heart failure.  
Mice were treated daily with vehicle and αAnalogue (50 nmol/kg, SC) postsurgery for 5 weeks (n=6–8). Ejection fraction (%) 
(A), septum wall thickness at diastole (mm) (B), left ventricle mass normalized to tibia length (mg/mm) (C), and wet lung mass 
(mg) normalized to tibia length (D). Representative images (E) and quantification of cardiomyocyte cross-sectional area (F) in 
heart using wheat germ agglutinin staining (scale bars, 20 µm). Quantification (G) and representative images (Continued )
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cular system benefited, irrespective of the continuing 
presence of AngII. This finding suggests that CGRP may 
act in an autoregulatory manner depending on CGRP 
peptide/agonist availability.
CGRP has positive chronotropic effects,31 and α-
CGRP KO mice exhibit exacerbated cardiac dysfunc-
tion in pressure overload–induced hypertrophy32 and 
deoxycorticosterone acetate salt–induced hyperten-
sion.33,34 Here, the αAnalogue had no effect on in 
vivo heart function, as observed by radiotelemetry or 
echocardiography in sham mice, but protected against 
cardiac hypertrophy in AngII-induced hypertension. 
The αAnalogue downregulated markers of fibrosis, re-
modeling, and hypertrophy, and protected against the 
reduction in the cardiac contractile dysfunction marker 
sarcoplasmic reticulum Ca2+ ATPase-2 in hypertensive 
hearts, as well. Our results correlate with previous in 
vitro findings35–37 and provide in vivo evidence that the 
αAnalogue has influential antiremodeling effects in the 
stressed heart, while not directly modulating normal 
heart activity in control mice.
The αAnalogue reduces cardiac inflammation, as 
shown by reducing AngII-induced increase in the che-
mokine RANTES. AngII increases hypoxia-inducible fac-
tor 1α mRNA expression, indicating the involvement 
of fibrotic and oxidative stress pathways, and this was 
reduced by the αAnalogue. CGRP regulates oxidative 
stress by the PI3K/Akt and mitogen-activated protein 
kinase signaling pathways,38 and deletion of the CGRP 
gene exacerbates cardiac oxidative stress in ischemia-
reperfusion injury.39 The αAnalogue protects against 
AngII-induced changes in the endogenous antioxidant 
defense responses and nitrosative stress. A link be-
tween CGRP and HO-1 is known.40 Activation of HO-1 
and NADPH dehydrogenase quinone-1 can counteract 
hypertension, potentially through generating the vaso-
dilator carbon monoxide41,42 and improved endothelial 
nitric oxide synthase coupling.43 Our data build on earli-
er findings in cardiomyocytes, smooth muscle cells, and 
α-CGRP KO mice, implying that the αAnalogue acts di-
rectly via its receptors on the heart and reduces stress-
activated kinases induced by oxidative stress,44 adverse 
tissue remodeling to preserve cardiac function.
Hypertension is associated with renal fibrosis and in-
flammation that were reduced by the αAnalogue, com-
plementing knowledge that CGRP promotes renal pro-
tection in hypertension independently of its vasodilator 
action.33,45 The αAnalogue preserved renal function by 
reducing mesangial matrix expansion, plasma and kid-
ney creatinine levels, and expression of cystatin C and 
neutrophil gelatinase-associated lipocalin, the early bio-
marker of acute kidney injury. AngII increases renal ad-
renergic receptors46 and we found a significant increase 
in renal noradrenaline content, which was reversed by 
the αAnalogue. Hence, the αAnalogue may preserve 
renal function by reducing sympathetic activity. Klotho 
has nephroprotective effects, and AngII-induced down-
regulation of klotho aggravates renal damage in hy-
pertension.24 This downregulation was rescued by the 
αAnalogue, and our results further confirm the link be-
tween klotho and CGRP.29 The upregulation of klotho 
associated with the use of αAnalogue may translate 
into enhanced renal protection in hypertension. The 
primary functional source of CGRP was reported to be 
independent of the kidney, because chemical denerva-
tion of renal sensory afferents removed tissue CGRP but 
without any beneficial effect in hypertensive mice.46 
However, our study highlights that mimicking sensory 
nerve efferent function by using an αCGRP analogue 
protects against end-organ damage in hypertension, 
especially renal fibrosis, a strong predictor of clinical 
progression of kidney disease.
Strikingly, the αAnalogue limits AngII-induced cardio-
vascular pathologies, ameliorating cardiac remodeling 
and fibrosis. This highlights the therapeutic potential of 
the αAnalogue when given in established hypertension. 
Although the αAnalogue was unable to reduce vascular 
endothelial dysfunction, it reduced markers of damage 
such as osteopontin, the downstream regulator of Akt 
activity,47 remodeling, fibrosis, and oxidative stress.7 The 
αAnalogue reduced both vascular and cardiac NOX-2 
expression. It is possible that many of the beneficial 
effects of the αAnalogue in both early or late onset 
of hypertension are primarily related to a decrease in 
blood pressure and the resultant reduction in pressure-
induced damage in the vasculature, kidney, and heart. 
Although it is presently difficult to separate the direct 
effects of the αAnalogue on pressure and cardiac func-
tion, it is evident that CGRP has antihypertensive effects 
and induces protection in a comprehensive manner.
To investigate the cardioprotective effects of the 
αAnalogue, we subjected mice to AAC and exam-
ined cardiac function. The adverse structural remod-
eling and hypertrophy at 5 weeks post-AAC, with 
significant reduction in ejection fraction and increas-
ing heart mass with fibrosis, were markedly attenu-
ated in αAnalogue-treated mice, under conditions 
where blood pressure was similar to αAnalogue and 
Figure 8 Continued. of fibrosis in heart (H) using picrosirius red staining (scale bars, 200 µm). Representative images (I) 
and quantification of capillary density in heart (J) using isolectin-B4 staining (scale bars, 20 µm). K and L, Protein expression 
of nitrotyrosine in heart. Quantification (M) and representative images of apoptosis (N) using TUNEL staining (scale bars, 50 
µm). Results showed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001 versus vehicle-treated sham mice; #P<0.05, ##P<0.01, 
###P<0.001 versus vehicle-treated AAC mice (2-way ANOVA + Bonferroni post hoc test). AAC indicates abdominal aorta con-
striction; α-CGRP, α-calcitonin gene–related peptide; and TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.
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vehicle-treated sham mice. This is consistent with 
findings where α-CGRP/calcitonin KO mice showed 
adverse cardiac dysfunction with increased mortality 
following transverse aortic constriction.32 Although 
CGRP infusion for 24 hours previously improved car-
diac performance in patients with chronic congestive 
heart failure,8,9 this is the first demonstration that 
chronic treatment with a long-lasting CGRP agonist 
is beneficial and well tolerated. Myocyte apoptosis 
is well documented in heart failure and CGRP regu-
lates cell survival signaling and antiapoptotic pathway 
via CLR/RAMP1 in cardiomyocytes.38,48 Although the 
αAnalogue reduces nuclear factor kappa B cells and 
apoptotic marker p53 expression in our acute AngII 
model, here, the αAnalogue reduced apoptosis, as re-
vealed in terminal deoxynucleotidyl transferase dUTP 
nick-end labeling staining with increased p38 mitogen-
activated protein kinase phosphorylation in the hyper-
trophic heart. Similarly, the αAnalogue maintained its 
antioxidant effects. Development of cardiac hypertro-
phy is associated with increased cardiomyocyte size and 
reduced capillary density, which ultimately lead to hy-
poxia and cell death.20 These changes were markedly 
reduced by the αAnalogue. This finding supports earlier 
studies where CGRP acted as a proangiogenic factor32,49 
and suggests that CGRP promotes normal cardiac mi-
crovessel development, perhaps via angiogenesis in hy-
pertrophic hearts. Further gene expression studies on 
ventricle tissues demonstrate that markers of heart fail-
ure were abrogated by the αAnalogue.
To our knowledge, this is the first study demonstrat-
ing that a long-lasting and stable α-CGRP agonist has 
the potential to act as a novel therapeutic agent, tar-
geting key mechanisms to benefit cardiovascular dys-
function, with limited adverse pathological changes 
and side effects. The results support the concept pro-
vided by in vitro studies that CGRP protects against ad-
verse remodeling, inflammation, oxidative stress, apop-
tosis, and end-organ damage in cardiovascular disease, 
in addition to its vasodilator activity. We thus propose 
that the CGRP pathway is a therapeutic target for the 
clinical treatment of cardiovascular disease and, more 
specifically, that injectable CGRP agonists may benefit 
heart failure.
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SUPPLEMENTAL MATERIAL 
Supplemental Methods  
Animals  
Male mice, CD1 (#022) or C57BL/6J (#027) (12-18 weeks of age), purchased from Charles River (Kent, 
UK) were used in all experiments. Blood flow experiments were performed on CD1 mice, whilst all 
other experiments with C57BL/6J mice. Mice were housed in a climatically controlled environment, on 
a 12-h light/dark cycle, with free access to water and standard food ad libitum. All experiments were 
conducted in accordance with the UK Home Office Animals (Scientific Procedures) Act, 1986 and were 
approved by the King’s College London Animal Care and Ethics Committee. All experiments were 
conducted in a blinded manner. Animals were randomly assigned to control or treatment groups and 
the experimenter was blinded towards treatment at the time of experiment. 
Cutaneous blood flow measurement by Full-field Laser Perfusion Imager 
Cutaneous blood flow was assessed in the whole area of ear, leg or paw area using the Full-field Laser 
Perfusion Imager (FLPI, Moor Instruments) on anaesthetised mice in their ventral positioned placed on 
a heating mat, maintained at 36°C, as previously described.1-3  
Local effects of α-CGRP analogue (αAnalogue, Figure 1, Supplemental Figure 1): CD1 mice were 
anaesthetised intraperitoneally (i.p.) with ketamine (75 mg/kg) and medetomidine (1 mg/kg).1 
Following recording of baseline blood flow in both ears to ensure the haemodynamic vascular responses 
have stabilised after anaesthesia, mice were injected intravenously (i.v.) with vehicle (neutralised saline) 
or CGRP receptor antagonist (BIBN4096, 0.3mg/kg)1, 4, 5 and blood flow was resumed for another 5 
min. The ipsilateral ear was then injected intradermally (i.d.) with αAnalogue6 (100pmol in 15µl, Novo 
Nordisk), whilst the contralateral ear received vehicle (0.219M Mannitol, 5% HPCD, 1.6% ammonium 
acetate at pH6.5). Initial experiments investigated other doses of αAnalogue (1-100pmol in 15µl). 
Changes in blood flow after these treatments were followed for 30 min. Results are expressed as (1) a 
measure of maximum % increase in blood flow from baseline or (2) arbitrary flux units (× 103 flux 
units) measured as area under the recorded flux (response curve) versus time for the entire recording 
period for 30 min following i.d. injection. 
Systemic effects of αAnalogue (Supplemental Figure 7): C57BL/6J mice were anaesthetised with 
isoflurane (2%, Abbott Laboratories) in 2l/min O2 and blood flow in the ear was measured for 5 min. 
Mice were allowed to recover and injected subcutaneously (s.c.) with vehicle (0.219M Mannitol, 5% 
HPCD, 1.6% ammonium acetate at pH 6.5) or αAnalogue (50nmol/kg, s.c., Novo Nordisk). At 1h 
following treatment, mice were anaesthetised and blood flow was measured for a further 5 min.  
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In other experiments, blood flow was measured for 5 min in the paw, leg and ear of mice treated daily 
with vehicle or αAnalogue (50nmol/kg, s.c., Novo Nordisk) for 14 days. Results are expressed as an 
average blood flow (flux units) for the 5 min for each area.  
Measurement of blood pressure via tail-cuff plethysmography  
Blood pressure was measured by tail-cuff plethysmography, using the CODA 8 non-invasive blood 
pressure acquisition technique system for mice (Kent Scientific), as previously described.7, 8 All 
measurements were taken at a thermoneutral ambient room temperature (25-27°C). C57BL/6J mice 
were warmed on a heating pad for 10 min prior to and during blood pressure recordings. Mice were 
trained for at least 10 consecutive days prior to baseline blood pressure measurements, to reduce stress-
induced changes caused by restraint.  
Dose-response characterisation of αAnalogue: Measurements were taken at baseline and 1, 6, 24 and 
30h following administration of vehicle (0.219M Mannitol, 5% HPCD, 1.6% ammonium acetate at pH 
6.5) or αAnalogue (10-100nmol/kg, s.c., Novo Nordisk).  
Measurement of blood pressure via carotid artery cannulation  
After 5 weeks of abdominal aortic construction (AAC)-cardiac hypertrophy and heart failure, mice were 
anaesthetised using isoflurane (2%, Abbott laboratories, UK) in 2L/min O2, where systemic blood 
pressure was monitored invasively9. The core temperature of the mice was maintained at 37°C with a 
homeothermic blanket (Havard apparatus, Cambridge, UK). Briefly, the left carotid artery was isolated 
and fluid-filled (heparin; 100U/ml diluted in 0.9% saline) cannula with an outer diameter of 0.7mm and 
internal diameter of 0.28mm (Smiths Medical-Portex, Hythe, UK) was introduced into the carotid 
artery. After a 5-min stabilisation period, systemic pressures were measured using PowerLab data 
acquisition system and LabChart 8 Pro software (ADInstruments Ltd, Oxfordshire, UK). Data was 
represented as an average of 10 min continuous recording.  
Measurement of blood pressure via radiotelemetry  
Blood pressure, heart rate and activity were measured using a radiotelemetry device (PA-C10, DSI, 
NL), with the catheter placed in the left carotid artery and advanced towards the aortic arch, as 
previously described1, 8, 10 in C57BL/6J mice. The catheter was secured using surgical braided silk (5.0, 
waxed, Pearsalls sutures) and the outer wound closed with absorbable sutures (5.0, Ethicon, Johnson 
and Johnson) in a discontinuous pattern. The transmitter was placed s.c. in the right flank and the 
transmitter pocket was irrigated with sterile saline (0.9% saline; sodium chloride, pyrogen free). All 
procedures were conducted using aseptic techniques under isoflurane anaesthesia (2%, Abbott 
Laboratories, UK) in 2l/min O2. Surgical anaesthesia was assessed by loss of the paw pinch reflex. 
Buprenorphine was administered intramuscularly (50 µg/kg, i.m., Vetergesic, Alstoe Animal Health) 
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for pain relief. All animals were singly housed and allowed to recover for 7-10 days before recording 
baseline blood pressure for three 3 nights and 2 days in a quiet room. Blood pressure, heart rate activity 
was monitored at 10 min intervals, for duration of 2 min using the DSI software (DSI Dataquest A.R.T.) 
and data analysed in Microsoft Excel and GraphPad Prism 5. Data are represented as an average of 6h 
measurement.  
Angiotensin-II murine hypertension model  
Following baseline blood pressure measurement using radiotelemetry, C57BL/6J mice were implanted 
s.c. in the mid-scapular region under isoflurane anaesthesia, with osmotic pump (1002; Alzet) 
containing Angiotensin II (AngII, Sigma) at a dose of 1.1mg/kg/day or saline (control) for 14 days, as 
previously described.7, 10 Blood pressure measurement using radiotelemetry was resumed. Mice were 
treated daily with vehicle (0.219M Mannitol, 5% HPCD, 1.6% ammonium acetate at pH 6.5) or 
αAnalogue6 (50nmol/kg, s.c., Novo Nordisk) at different time-points, as detailed below.  
Experimental design 1: Animals were divided into four groups: vehicle (saline), vehicle (AngII), 
αAnalogue (saline) and αAnalogue (AngII). Following, saline or AngII osmotic pump infusion, mice 
received daily treatment of vehicle or αAnalogue (50nmol/kg, s.c., Novo Nordisk) at Day 1 to Day 14 
of AngII infusion (Figure 2). Total food intake (g), water consumption (ml) and body weight (g) was 
recorded throughout the study.  
Experimental design 2: Animals were divided into two groups: vehicle (AngII) and αAnalogue (AngII). 
All mice received osmotic pumps containing AngII (1.1mg/kg/day) and at day 7 following AngII 
infusion when mice showed a significant increase in blood pressure from baseline, they received daily 
treatment of vehicle or αAnalogue (50nmol/kg, s.c., Novo Nordisk) at Day 7 to Day 14 of AngII 
infusion (Figure 6). 
At the end of the study (Day 15), mice were briefly anaesthetised with isoflurane (Abbott Laboratories) 
in 2l/min O2 and blood was collected via cardiac puncture. Mice were culled by cervical dislocation and 
organs (heart and aorta) were harvested for post-analysis. Heart, lung, kidney and spleen from each 
mouse was excised, dried on filter paper and weighed. Organs’ weights were normalised to body weight 
and tibia length.  
Cardiac hypertrophy murine model  
Mice were surgically subjected to pressure-overload induced-cardiac hypertrophy and heart failure as 
previously described.11 Briefly, suprarenal aortic constriction was performed in anesthetised mice (2% 
isoflurane carried in O2, Abbott Laboratories), where the abdominal aorta was ligated to the width of a 
28G needle (0.36mm) using suture thread (8-0, Ethilon Sutures, Ethicon) in between the superior 
mesenteric and celiac bifurcation. Sham surgeries were performed in the same manner, excluding the 
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constriction. Post-surgery analgesia was provided in the form of buprenorphine (50 µg/kg, i.m., 
Vetergesic). Following surgery, mice were treated with daily with vehicle (0.219M Mannitol, 5% 
HPCD, 1.6% ammonium acetate at pH 6.5) or αAnalogue6 (50nmol/kg, s.c., Novo Nordisk) for 5 weeks. 
Body weight, food and water intake were measured throughout the study. At the end of week 5, mice 
were briefly anaesthetised with isoflurane (Abbott Laboratories) in in 2l/min O2 and blood was collected 
via cardiac puncture. Mice were culled by cervical dislocation and organs were harvested for post-
analysis. Heart, lung, kidney and spleen from each mouse was excised and weighed. Organs’ weights 
were normalised to body weight and tibia length.  
Echocardiography  
Anesthesia in mice was induced in a chamber with 5% isoflurane for 1 min, afterwards maintained with 
1.5% on a heated platform. Imaging was performed 10 min after induction using a Vevo 2100 Imaging 
System with a 40-MHz linear probe (Visualsonics, Canada), as previously described.11, 12 Cardiac 
dimensions as well as systolic function were assessed using M-mode imaging in long axis views. The 
relative wall thickness (RWT) in diastole was calculated as follows: RWT = (septal wall thickness + 
posterior wall thickness) / left ventricular diameter. Data analysis was performed with Vevo®2100 
software v.1.2.1 (Visualsonics). 
Light aversion assay 
The light aversion assay is based on rodents’ natural preference for darker areas compared to lighter 
areas13, 14 and was used to study photophobia in rodents, a common symptom of migraine.15 The 
apparatus consisted of two equal compartments: one-half (20 (d) x 20 (w) x 14 (h) cm) black plexiglass, 
with a black lid on top, the remaining half was transparent to enable behavioural assessment and 
recording. Mice were able to move freely between the two compartments through a small doorway (5 
× 5 cm) in the center of the black plexiglass wall separating the two compartments, as described 
previously.14 Lighting conditions (1000 lux) were established with the aid of 100-watt incandescent 
lamp, placed 45 cm above the centre of the box floor to the test arena and confirmed with a luxmeter 
(Mastech Light Meter, LX1010B, Mestech UK). At 1000 lux, light intensities in the dark zone were 
about 200 lux immediately inside the opening, 30 lux at the back wall across from the opening, and 10 
lux at all four corners. 
Mice were trained in the light/dark box under a range of lighting conditions (500-1000 lux) twice for 7 
days. Mice that displayed equal preference between light/dark compartments (>40% light preference) 
were used in our study. Following acclimation in the testing room for 1h (200 lux), baseline recordings 
(10 min) were obtained, followed by systemic administration of vehicle (0.219M Mannitol, 5% HPCD, 
1.6% ammonium acetate at pH 6.5) or αAnalogue (50 nmol/kg, s.c.) or the positive control glyceryl 
trinitrate (GTN, 320 nmol/kg, i.v.). Behavioural responses were resumed for 10min at 2h following 
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treatment.16  
To evaluate the effects of chronic administration of the αAnalogue (5 weeks), sham mice were assessed 
on week 5 for light aversion at 1h following systemic administration of vehicle (0.219M Mannitol, 5% 
HPCD, 1.6% ammonium acetate at pH 6.5) or αAnalogue (50 nmol/kg, s.c.); behavioural responses 
were recorded for 10min.  
Mouse behaviour was digitally recorded using an IPEVO camera (IPEVO, UK), placed 30cm above 
the light/dark box and attached to a laptop. Videos were continuously recorded at 30 frames/s and 
decomposed to individual frames of 1s interval. Each 10min experimental interval was taken to start 
immediately after the mouse entered the dark chamber. Behavioural experiments were conducted by a 
blinded observer and analysis was conducted procedurally with a custom ImageJ script, applying 
foreground extraction to determine the presence of the mouse against the white background of the light 
box floor across sequential frames. Absolute duration and % dwell time within the light and dark 
chambers was automatically calculated, as was the number of transitions, interpreted as crossings. Data 
was represented as the % of time spent in light during the 600s test session. 
Glucose tolerance test  
Glucose tolerance tests (GTT) were performed following a 6h fast (from 08:30 to 14:30), as previously 
described.17 Glucose (1g/kg, Sigma) was injected i.p. and blood glucose levels were monitored for 2h 
(from 08:30 to 14:30) at the indicated time points after injection with a One Touch Vita glucose meter 
(Lifescan, UK). GTT was determined at baseline and at Day 14 following daily treatment with the 
αAnalogue (50nmol/kg, s.c.) or its respective vehicle (0.219M Mannitol, 5% HPCD, 1.6% ammonium 
acetate at pH 6.5).  
Core body temperature measurement using radiotelemetry 
Core body temperature and activity were measured using radio-telemetry as described previously.18 
Briefly, animals were anaesthetised by isoflurane (2%, Abbott Laboratories, UK) in 2l/min O2, placed 
on a homeothermic heating pad and buprenorphine (50µg/kg, i.m., Vetergesic, Alstoe, Animal Health, 
UK) was administered peri-operatively. The abdomen was shaved and scrubbed using surgical scrub 
and a small ventral midline abdominal incision (< 2 cm) was made to expose the abdominal muscle 
wall. A ventral incision was made on the abdominal wall and a small volume of (< 80 µl) sterile saline 
was applied to facilitate the insertion of the radio telemetry transmitter (TA10TA-F10; DSI, St Paul, 
Minnesota, USA). Following implantation, the abdominal wall and skin were sutured separately using 
absorbable sutures (Vicryl ® 4.0, Ethicon, Johnson & Johnson, UK). The mice were monitored until 
ambulatory and were individually housed with food and water ad libitum. Mice were weighed and 
examined daily, and were allowed a minimum 7 days post-surgical recovery period. Cages containing 
the telemetered animals were placed on the receiver plates (RPC-1; Data Sciences Incorporated (DSI, 
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Minnesota, USA); radio signals from the implanted transmitters were monitored via a fully automated 
data acquisition system (DataquestART, version 3.1; DSI, Minnesota, USA). Locomotor activity and 
core body temperature were monitored at 10 min intervals, for duration of 2 min. 
Following baseline measurement for 1h, the αAnalogue (50nmol/kg, s.c.) and its respective vehicle 
(0.219M Mannitol, 5% HPCD, 1.6% ammonium acetate at pH 6.5) were administered s.c. and 
measurements were recorded for 24h thereafter.  
Measurement of gene expression using Real-time reverse transcription polymerase chain reaction 
Real-time reverse transcription polymerase chain reaction (RT-qPCR) was carried out as previously 
described.3, 7, 10  
Total ribonucleic acid (RNA) was extracted from aorta, heart and kidney tissue using the Qiagen 
RNeasy Microarray tissue mini Kit (Qiagen), according to manufacturer’s instructions. Total RNA 
(1µg) was then reverse transcribed into cDNA using the High Capacity RNA-to-cDNA Kit (Applied 
Biosystems, Life technologies Ltd) as per manufacturer’s instructions. A thermal cycler (DNA Engine 
Tetrad 2 Peltier Thermal Cycler) was used for reverse transcription to complementary DNA (cDNA). 
Negative RT samples were carried out as a control to exclude possible contamination of genomic DNA. 
cDNA was then diluted 1:40 in nuclease-free water for RT-qPCR. Quantitative PCR (qPCR) was then 
conducted using a SYBR-green-based PCR mix (Sensi-Mix, SYBR-green No ROX; Bioline) and 
primers from the specific gene of interest pipetted into 100-well gene disks (Qiagen) by an automated 
robot (CAS1200; Qiagen Corbett), followed by PCR in a Corbett Rotor-gene 6000. Settings were as 
follows; initial denaturation: 10min at 95°C; cycling: 45 cycles- 10 s at 95°C, 15 s at 57°C, and 5s at 
72°C; melt: 68-90°C. Samples were subjected to melting curve analysis to confirm amplification 
specificity. Data were collected as copies/µl and normalised against murine hypoxanthine phosphor-
ribosyltransferase (HPRT), β-2-microglobulin (B2M) and β-actin expression using GeNorm3.4 
software. A list of primers are summarised in Supplemental Table I.  
Western blotting  
Western blot analysis was performed as previously described.1, 2, 7 Briefly, aorta, mesentery, heart and 
kidney tissue was homogenised in SDS lysis buffer containing protease inhibitor (1tablet/50ml, Roche, 
Germany) and protein concentrations were determined. Samples were loaded onto a 7-12% Tris SDS- 
polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes 
using a semi-dry technique (Bio-Rad). After blocking with 5% non-fat dry milk, membranes were 
incubated with a primary antibody (4°C, overnight), and incubated with the secondary antibody at room 
temperature for 1h. Proteins were detected by enhanced chemiluminescence (ECL, Piercenet) and 
developed using the Syngene gel doc dark room system. Densitometric analysis was performed using 
Image J analysis software (NIH, USA). Antibodies against eNOS (1:500, Ab5589), HO-1 (1:500, 
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Ab13248), nitrotyrosine (1:500, Ab61392)2, GPX-1 (1:1000, Ab22604), CLR (1:500, Ab173562) and 
RAMP1 (1:1000, Ab156575) were purchased from Abcam. Antibodies against NOX-2 (gp91phox, 
1:500, 611414) were obtained from BD Transduction, α-SMA (1:1000, A2547) from Sigma and klotho 
(1:500, KM2076) from Cosmo Bio Co. Ltd. p-p38 (1:1000, 9216) and total-p38 (1:1000, 9212) were 
purchased from Cell Signalling. GAPDH (1:4000, AM4300) was purchased from Life Technologies 
Ltd and used for a loading control. Note that for nitrosylated proteins detected using anti-nitrotyrosine 
antibody, densitometric analysis was conducted for the entire lane and normalised to GAPDH. 
Quantification of noradrenaline using ELISA 
Plasma and renal noradrenaline (NA) content were quantified using a commercially available NA 
ELISA kit (RE59261; IBL International, Hamburg, Germany), as previously described.1 Briefly, 
kidneys were homogenised in phosphate buffered saline (1M), supplemented with protease inhibitors 
(Roche, Germany). Lysates were cleared by centrifugation at 2,600 g for 15 min at 4°C. NA content 
was extracted from both plasma and kidney tissue lysate and assessed by standard ELISA technique, 
according to the manufacturer instructions. The limit of sensitivity was 20 pg/ml and the linearity limit 
was 8.0 ng/ml. Cross-reactivity to other catecholamines or metabolites was manufacturer tested as 
<0.02%. Protein concentration of each kidney samples were determined by Bradford dye-binding 
method (Bio-rad) and noradrenaline content was normalised to mg of protein.  
Quantification of IL-6 and TNF-α using ELISA 
Briefly, frozen kidney tissues were homogenised in phosphate buffered saline (1M), supplemented with 
protease inhibitors (Roche, Germany). Lysates were cleared by centrifugation at 2,600 g for 15 min at 
4°C. Renal interleukin-6 (IL-6) and Tumour necrosis factor-α (TNF-α) content were quantified using a 
commercially available ELISA kit (RAB0308 & RAB0477, Sigma, UK), following manufacturer’s 
protocol. Protein concentration of each kidney samples were determined by Bradford dye-binding 
method (Bio-rad). The final concentrations of both IL-6 and TNF-α were calculated with respect to the 
total amount of protein (mg). 
Histology 
Aorta, heart and kidney tissues were fixed in 4% paraformaldehyde (overnight, 4°C), as previously 
described.7, 19, 20 For heart and kidney samples, after routine paraffin wax embedding, transverse sections 
(6µm) were prepared using a Reichert-Jung 2030 Biocut microtome onto poly-L-lysine slides. For aorta 
samples, following fixation aorta segments were embedded in optimal cutting temperature compound 
(OCT, VWR), frozen on dry ice in a cryomould and cryosectioned on a microtome cryostat (6µm, 
Bright, UK) on Superfrost Plus glass slides. Sections were allowed to dry overnight. Approximately 8-
10 transverse sections were obtained from each heart or aorta per mouse for staining.  
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Aorta Staining: Sections of aorta were stained with Masson’s trichrome, as previously described7, 21. 
All slides were imaged using an Olympus Colourview III camera, connected to an Olympus BX51 
microscope (x10 magnification). Images were taken using CellSens Dimension viewing software 
(Version 1.1.3, Olympus). Aortic wall width (medial thickness) were measured (mean of 8 
measurements taken from at least 3 sections for each 4 mice/group) using ImageJ analysis software 
(scale bars, 100µm; NIH, USA). 
Heart Staining: Picrosirius Red (0.1% w/v) staining was used to visualise collagen fibres in the heart20 
and fibrosis was assessed blindly. All slides were imaged using a Leica Diaplan microsope (x10 
magnification) and images captured using ProgRes Capture Pro viewing software (Version 2.8.8, 
JENOPTIK) under bright light and circular polarised light according to a modified Junqueira method.22, 
23 Cardiac fibrosis was quantified on circular polarised light images using Image J analysis software 
(scale bars, 200µm; NIH, USA).  
Conjugated wheat germ agglutinin (WGA, CF488A, Biotium) staining was applied to outline 
cardiomyocyte boundaries and quantify cross-sectional area.20 All slides were imaged using an 
Olympus Colourview III camera, connected to an Olympus BX51 microscope (x40 magnification). 
Images were taken using CellSens Dimension viewing software (Version 1.1.3, Olympus). Myocyte 
cross-sectional area was employed as an index of cardiac hypertrophy and determined on fibres with 
circular shapes in a blinded fashion by quantitative image analysis using Image J (scale bars, 20µm; 
NIH, USA). 
Capillaries were immunostained with isolectin B4 (Vector B-1205) and capillary density was quantified 
as the number of capillaries per mm2 of LV sections11. All slides were imaged using an Olympus 
Colourview III camera, connected to an Olympus BX51 microscope (x40 magnification). Images were 
taken using CellSens Dimension viewing software (Version 1.1.3, Olympus). Number of capillaries 
were manually counted in a blinded fashion by quantitative image analysis using Image J (scale bars, 
20µm; NIH, USA). 
Apoptosis was detected by using terminal deoxyribonucleotide transferase (TdT)-mediated dUTP nick-
end labelling (TUNEL) staining (Millipore S7111 kit) in LV sections24. All slides were imaged using 
an Olympus Colourview III camera, connected to an Olympus BX51 microscope (x20 magnification). 
Images were taken using CellSens Dimension viewing software (Version 1.1.3, Olympus). TUNEL-
positive myocytes and DAPI-stained nuclei were manually counted by quantitative image analysis using 
Image J (scale bars, 50µm; NIH, USA).  
Kidney Staining: Sections of kidney were stained with Periodic acid–Schiff’s (PAS) and counter stained 
with hematoxylin, as previously described25. All slides were imaged using an Olympus Colourview III 
camera, connected to an Olympus BX51 microscope (x40 magnification). Images were taken using 
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CellSens Dimension viewing software (Version 1.1.3, Olympus). A semi quantitative system was used 
to grade mesangial expansion by either diffuse (irregular streaks) or segmental (localized to a lobule) 
type. In each of the experimental animals, 20 glomeruli were examined for mesangial expansion and 
each glomerulus was graded 0 to 4 corresponding to the percentage of mesangial 
matrix covering/occupying the urinary space of the Bowman’s capsule. Glomeruli were assessed and 
graded 1-4, as follows: grade 1, involvement of 0-24%; grade 2, 25-29%; grade 3, 50-74% or grade 4; 
75-100% of mesangial area to Bowman’s capsule (scale bars, 20µm; NIH, USA). Mean glomerular 
score index was determined for each kidney26.  
All morphometric measurements were performed in a blinded manner. 
Statistical analysis 
Data in the manuscript is expressed as mean + SEM. Statistical analysis was performed using a two-
tailed Student’s t-test (2 unpaired groups), one-way or repeated measures two-way analysis of variance 
(ANOVA) followed by Bonferroni’s comparison post hoc test (multiple groups comparison). p<0.05 
was considered to represent a significant difference. 
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Supplemental Tables 
Supplemental Table 1. Gene primer sequences  
Target Gene Primer Sequence Accession number 
Akt 
F: CGTCGCCAAGGATGAGGTTG 
NM_001165894.1 
R: GTCGTGGGTCTGGAATGAGT 
α-MHC 
F: GCTGGAAGAAAAGCTCAAGAAGAAA 
NM_001164171.1 
R: TCTCTATCTGCACGGATGTGG 
β-MHC 
F: CACCTACCAGACAGAGGAAGA 
NM_080728.2 
R: GGAGCTGGGTAGCACAAGA 
α-skeletal actin 
F: CTAAATCCAAGTCCTGCAAGTG 
NM_001272041.1 
R: ACATGGTGTCTAGTTTCAGAGG 
ANP 
F: GGATTTCAAGAACCTGCTAGACC 
NM_008725.3 
R: GCAGAGCCCTCAGTTTGCT 
B2M 
F: GTCGCTTCAGTCGTCAGCA 
NM_009735.3 
R: TTGAGGGGTTTTCTGGATAGCA 
Bcl-2 
F: AGGCTGGGATGCCTTTGTGG 
NM_009741.5 
R: TGTTTGGGGCAGGTTTGTCG 
BNP 
F: TGGGCTGTAACGCACTGAA 
NM_001287348.1 
R: TGTTGTGGCAAGTTTGTGCTT 
Collagen Type 1 α1 
F: TCTGACTGGAAGAGCGGAGAG 
NM_007742.4 
R: AGACGGCTGAGTAGGGAACA 
Collagen Type 1 α2 
F: TGGATACGCGGACTCTGTTG 
NM_007743.2 
R: CCCTTTCGTACTGATCCCGATT 
Collagen Type 3 α1 
F: GGGAGGAATGGGTGGCTATC 
NM_009930.2 
R: CTGGGCCTTTGATACCTGGA 
Collagen Type 4 α1 
F: CTGGAGAAAAGGGCCAGAT 
NM_009931.2 
R: TCCTTAACTTGTGCCTGTCC 
CTGF 
F: GGGCCTCTTCTGCGATTC 
NM_010217.2 
R: ATCCAGGCAAGTGCATTGGTA 
Cystatin C 
F: GAGTACAACAAGGGCAGCAAC 
NM_009976.4 
R: AGCAGAGTGCCTTCCTCATCA 
eNOS 
F: GACCCTCACCGCTACAA AT 
NM_008713.4 
R: GTCCTGGTGTCCAGATCCAT 
Fibronectin 
F: CCGGTGGCTGTCAGTCAGA 
NM_006495700.2 
R: CCGTTCCCACTGCTGATTTATC 
GPX-1 
F: TTCGGACACCAGGAGAATGG 
NM_008160.6 
R: TAAAGAGCGGGTGAGCCTTC 
HIF-1α 
F: CGAGAACGAGAAGAAAAAGATGAGT 
NM_010431.2 
R: CGTAAATAACTGATGGTGAGCCT 
HO-1 
F: CAACATTGAGCTGTTTGAGGAG 
NM_010442.2 
R: CTCTGACCAAGTGACGCCAT 
 F: CCTGGTTCATCATCGCTAATC NM_013556.2 
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HPRT R: TCCTCCTCAGACCGCTTTT 
MMP-2 
F: GACAAGTTCTGGAGATACAATGAAGTG 
NM_006530751.1 
R: CAGGTTATCAGGGATGGCATTC 
NGAL 
F: AATGTCACCTCCATCCTGGTCA 
NM_008491.1 
R: GACAGCTCCTTGGTTCTTCCATAC 
NF-κB 
F: CCTACGGAACTGGGCAAATGT 
NM_ 008689.2 
R: TCCCCTCTGTTTTGGTTGCT 
NOX-2 
F: ACTCCTTGGGTCAGCACTGG 
NM_007807.5 
R: GTTCCTGTCCAGTTGTCTTCG 
NQO1 
F: TCATTCTCTGGCCGATTCA 
NM_008706.5 
R: TGCTGTAAACCAGTTGAGGTTC 
Osteopontin 
F: AAACCAGCCAAGGTAAGCCT 
NM_001204201.1 
R: GCAAAAGCAATCACTGCCA 
p53 
F: ATGCCCATGCTACAGAGGAG 
NM_001127233.1 
R: AGACTGGCCCTTCTTGGTCT 
RANTES 
F: TGCTCCAATCTTGCAGTCGT 
NM_013653.3 
R: GCGTATACAGGGTCAGAATCAAG 
SERCA-2 
F: TGGAACCTTTGCCGCTCATTT 
NM_009722.3 
R: CAGAGGCTGGTAGATGTGTT 
TGF-β1 
F: TCAGACATTCGGGAAGCAGT 
NM_011577.2 
R: GCCCTGTATTCCGTCTCCTTG 
TIMP-2 
F: GATTCAGTATGAGATCAAGCAGATAAAGA 
NM_011594.3 
R: GCGAGACCCCGCACACT 
α-SMA 
F: ACTACTGCCGAGCGTGA 
NM_007392.3 
R: ATAGGTGGTTTCGTGGATGC 
β-actin 
F: CACAGCTTCTTTGCAGCTCCTT 
NM_007393.5 
R: TCAGGATACCTCTCTTGCTCT 
Supplemental Table 1. List of gene primer sequences used for qRT-PCR studies. 
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Supplemental Table 2: Changes in organ weight in AngII and saline-infused mice pre-treated 
with αAnalogue or vehicle 
Organs 
Vehicle αAnalogue 
Saline AngII Saline AngII 
Total Heart:Body Weight (mg/g) 4.4 + 0.3 6.3 + 0.2 *** 4.5 + 0.2 5.2 + 0.2 †† 
Total Heart:Tibia length (mg/mm)  7.9 + 0.4 10.0 + 0.4 *** 7.5 + 0.2 8.4 + 0.3 †† 
Left Ventricle:Body Weight (mg/g) 3.4 + 0.2 4.9 + 0.1 *** 3.5 + 0.2 4.2 + 0.1 ††† 
Lung Oedema (Wet:Dry Ratio) 4.2 + 0.1 4.2 + 0.1 4.1 + 0.1 4.1 + 0.1 
Kidney:Body Weight (mg/g) 5.8 + 0.3 5.8 + 0.3 5.8 + 0.3 5.7 + 0.2 
Kidney:Tibia length (mg/mm) 10.8 + 0.3 9.1 + 0.4 9.4 + 0.2 9.4 + 0.6 
Spleen:Body Weight (mg/g) 2.5 + 0.2 3.1 + 0.2 2.7 + 0.2 3.1 + 0.3 
Spleen:Tibia length (mg/mm) 4.7 + 0.2 4.8 + 0.3 4.5 + 0.3 5.1 + 0.4 
Supplemental Table 2. Changes in organ weight in the heart of AngII and saline-infused mice 
treated daily with α-CGRP analogue (αAnalogue, 50nmol/kg) or vehicle (s.c.) daily for 14 days. 
Mice were implanted with osmotic pumps containing saline or AngII (1.1mg/kg/day) and treated daily 
with vehicle or αAnalogue (50nmol/kg, s.c.) for 14 days (n=6-9). At day 15, mice were sacrificed, 
organs were weighed and normalised to body weight (mg/g) or tibia length (mg/mm). Results show 
mean + SEM. ***p<0.001 vs vehicle-treated saline-infused mice; ††p<0.01, †††p<0.001 vs vehicle-
treated AngII-infused mice (2-way ANOVA + Bonferroni post hoc test).  
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Supplemental Table 3: Changes in gene expression in the heart of AngII and 
saline-infused mice pre-treated with αAnalogue or vehicle 
Gene 
Vehicle αAnalogue 
Saline AngII Saline AngII 
CTGF  89.3 + 14.6 220.3 + 44.0 * 152.0 + 42.9 67.6 + 20.1 † 
Akt  499.1 + 80.1 721.8 + 96.6  666.7 + 78.6 365.7 + 59.3 † 
TIMP-2 337.6 + 22.5 396.2 + 33.5 391.5 + 52.1 223.5 + 30.0 *, †† 
NF-κB 231.6 + 16.5 263.6 + 25.2 276.9 + 14.6 185.3 + 12.7 **, † 
Bcl-2 16.0 + 1.5 17.3 + 2.0 13.5 + 2.1 12.7 + 1.7 
p53 5082 + 569.4 7267 + 543.1 * 6475 + 518.5 4926 + 359.5 †† 
 
Supplemental Table 3. Changes in gene expression in in the heart of AngII and saline-infused 
mice treated daily with α-CGRP analogue (αAnalogue, 50nmol/kg) or vehicle (s.c.) daily for 14 
days. Mice implanted with osmotic pumps containing saline (S) or AngII (A, 1.1mg/kg/day) and treated 
daily with vehicle or αAnalogue (50nmol/kg, s.c.) for 14 days. mRNA expression measured by qRT-
PCR (n=5-11) for connective tissue growth factor (CTG), Protein Kinase B (PKB, Akt), tissue inhibitor 
of metalloproteinase-2 (TIMP-2), nuclear factor kappa B cells (NF-κB), apoptosis regulator B-cell 
lymphoma 2 (Bcl-2) and apoptotic marker p53 in the mice heart. Results expressed as copy numbers 
per µl normalised to HPRT, B2M and β-actin. Results show mean + SEM. *p<0.05 vs vehicle-treated 
saline-infused mice; †p<0.05, ††p<0.01 vs vehicle-treated AngII-infused mice (2-way ANOVA + 
Bonferroni post hoc test). 
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Supplemental Table 4. Changes in gene expression in the aorta of vehicle 
and αAnalogue treated AngII-infused mice 
Gene 
AngII 
Vehicle αAnalogue 
Vascular dysfunction     
eNOS 210.2 + 14.4 162.2 + 31.5 
Akt 663.3 + 23.6 567.9 + 30.1 * 
      
Remodelling and fibrosis     
TGF-β 3282.2 + 395.3 1567.4 + 412.6 * 
CTGF 2957.2 + 270.3 1513.3 + 412.6 * 
COL1A1 8869.7 + 2537.2 5253.2 + 1553.8 
COL3A1 2765.6 + 802.5 1139.5 + 325.45 
α-SMA 5288.1 + 343.5 3272.2 + 271.6 ** 
      
Vascular Inflammation     
RANTES 2524.6 + 1132.0 928.9 + 228.8 
Osteopontin 36.0 + 10.9 4.8 + 2.4 * 
      
Oxidative Stress      
HO-1 1169.0 + 349.0 226.3 +68.2 * 
NOX-2  52.8 + 1.4 32.3 + 2.8 ** 
 
Supplemental Table 4. Changes in gene expression in the aorta of vehicle and α-CGRP analogue 
(αAnalogue) treated Angiotensin II (AngII)-infused mice. Mice infused with AngII (1.1mg/kg/day) 
and treated daily with vehicle or αAnalogue (50nmol/kg, s.c.) at day 7 to 14. mRNA expression 
measured by qRT-PCR (n=4) for endothelial nitric oxide (eNOS), Protein kinase B (PKB, Akt), 
transforming growth factor beta-1 (TGF-β1), connective tissue growth factor (CTGF), collagen type 1 
α1 (COL1A1), collagen type 3 α1 (COL3A1), alpha-smooth muscle actin (α-SMA), RANTES, 
osteopontin, haem-oxygenase 1 (HO-1), NAD(P)H dehydrogenase, quinone-1 (NQO1) and NADPH 
oxidase-2 (NOX-2) in the mice aorta. Results expressed as copy numbers per µl normalised to HPRT, 
B2M and β-actin. Results are shown as mean + SEM. *p<0.05, **p<0.01 vs vehicle-treated AngII-
infused mice (two-tailed Student t-test). 
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Supplemental Table 5: Changes in organ weight in αAnalogue 
or vehicle-treated AngII-induced hypertensive mice  
Organs AngII 
Vehicle αAnalogue 
Total Heart:Body Weight (mg/g) 6.3 + 0.5 4.9 + 0.2 * 
Total Heart:Tibia length (mg/mm)  9.4 + 0.4 7.5 + 0.6 * 
Left Ventricle:Body Weight (mg/g) 5.2 + 0.4 3.9 + 0.1 * 
Lung Oedema (Wet:Dry Ratio) 3.7 + 0.2 3.9 + 0.3 
Kidney:Body Weight (mg/g) 5.8 + 0.3 5.3 + 0.3 
Kidney:Tibia length (mg/mm) 8.4 + 0.2 8.2 + 0.1 
Spleen:Body Weight (mg/g) 2.6 + 0.3 2.9 + 0.2 
Spleen:Tibia length (mg/mm) 3.8 + 0.3 4.5 + 0.6 
 
Supplemental Table 5. Changes in organ weight in the heart of α-CGRP analogue (αAnalogue, 
50nmol/kg) or vehicle (s.c.)-treated AngII-infused mice. Mice were infused with AngII 
(1.1mg/kg/day) osmotic pumps for 14 days and treated with vehicle or αAnalogue (50nmol/kg) on Day 
7-14 (n=4). At day 15, mice were sacrificed, organs were weighed and normalised to body weight 
(mg/g) or tibia length (mg/mm). Results show mean + SEM. *p<0.05 vs vehicle-treated AngII-infused 
mice (two-tailed Student t-test).  
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Supplemental Table 6: Changes in gene expression in the heart of vehicle 
and αAnalogue treated AngII-infused mice  
Gene 
AngII 
Vehicle αAnalogue 
Remodelling and fibrosis     
CTGF 1118 + 85.6 719.0 + 206.3 
Fibronectin  586.0 + 62.0 330.6 + 87.6 
COL1A1 825.5 + 140.0 569.3 + 157.8 
COL3A1 852.2 + 140.0 282.5 + 91.9 * 
COL4A1 4670.9 + 415.7 4108.7 + 512.0 
SERCA-2 189.2 + 13.5 163.7 + 18.7 
ANP 40224 + 7485.1 6026.7 + 2559.2 ** 
BNP 1365.6 + 220.9 1517.8 + 641.2 
   
Oxidative Stress      
NOX-2  67.7 + 7.1 44.4 + 3.9 * 
 
Supplemental Table 6. Changes in gene expression in the heart of vehicle and α-CGRP analogue 
(αAnalogue) treated Angiotensin II (AngII)-infused mice. Mice infused with AngII (1.1mg/kg/day) 
and treated daily with vehicle or αAnalogue (50nmol/kg, s.c.) at day 7 to 14 (n=4). mRNA expression 
measured by qRT-PCR for connective tissue growth factor (CTGF), fibronectin, collagen type 1 α1 
(COL1A1), collagen type 3 α1 (COL3A1), collagen type 4 α1 (COL4A1), sarcoplasmic reticulum Ca2+ 
ATPase-2 (SERCA-2), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and NADPH 
oxidase-2 (NOX-2) in heart. Results expressed as copy numbers per µl normalised to HPRT, B2M and 
β-actin. Data represent mean + S.E.M. *p<0.05, **p<0.01 vs vehicle-treated AngII-infused (two-tailed 
Student t-test). 
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Supplemental Table 7. Echocardiographic parameters of left ventricular size and function 5 
weeks post AAC-induced hypertrophy and heart failure in mice treated with αAnalogue or 
vehicle 
Parameters Vehicle αAnalogue 
Sham AAC Sham AAC 
n 8 6 8 8 
HR [bpm] 430.3 + 11.59 455.5 + 36.49 452.9 + 10.37 457.9 + 17.49 
LVID;d [mm] 4.18 + 0.10 4.36 + 0.13 4.10 + 0.11 4.32 + 0.07 
LVID;s [mm] 3.16 + 0.08 3.68 + 0.21* 3.01 + 0.09 3.32 + 0.09 
LVV;d [µl] 40.14 + 2.43 59.04 + 7.82** 35.76 + 2.80 45.13 + 3.04 
LVV;s [µl] 78.41 + 4.39 86.44 + 5.97 75.00 + 4.98 84.61 + 3.16 
septW [mm] 0.78 + 0.03 1.02 + 0.04 *** 0.79 + 0.03 0.87 + 0.03 †† 
postW [mm] 0.74 + 0.03 1.03 + 0.06 *** 0.71 + 0.03 0.78 + 0.02 ††† 
rWT 0.37 + 0.02 0.47 + 0.02 ** 0.37 + 0.02 0.38 + 0.01 †† 
SV [µl] 38.27 + 2.30 27.40 + 2.7 ** 39.24 + 2.43 39.48 + 1.34 †† 
EF [%] 48.80 + 1.17 33.10 + 5.17 *** 52.51 + 1.24 46.87 + 1.96 †† 
FS [%] 24.39 + 0.72 15.91 + 2.92 *** 26.67 + 0.79 23.37 + 1.17 †† 
 
Supplemental Table 7. Echocardiographic parameters of left ventricular size and function 5 
weeks post AAC-induced hypertrophy and heart failure. Mice were treated daily with vehicle or α-
CGRP analogue (αAnalogue, 50nmol/kg/day, s.c.) post surgery (n=6-8). (HR: heart rate, LVID;d: left 
ventricular dimension in diastole, LVID;s: left ventricular dimension in systole, LVV;d: left ventricular 
volume in diastole, LVV;s: left ventricular volume in systole, septW: septal wall thickness, postW: 
posterior wall thickness, rWT: relative wall thickness, SV: stroke volume, EF: ejection fraction, FS: 
fractional shortening. Data represented as mean ± SEM (n=6-8). *p<0.05, **p<0.01, ***p<0.001 vs 
respective sham-treated; ††p<0.01, †††p<0.001 vs vehicle-treated AAC (2-way ANOVA + Bonferroni 
post hoc test).  
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Supplemental Table 8: Changes in organ weight in AAC and sham-treated WT mice pre-treated 
with αAnalogue or vehicle 
Organs Vehicle αAnalogue 
Sham  AAC Sham AAC 
Total Heart:Body Weight (mg/g) 4.7 + 0.1 9.1 + 0.1*** 4.7 + 0.2 5.9 + 0.3††† 
Total Heart:Tibia length (mg/mm)  7.6 + 0.2 13.8 + 1.2*** 7.8 + 0.3 9.6 + 0.5††† 
LV:Body Weight (mg/g) 3.5 + 0.1 7.1 + 0.6*** 3.5 + 0.1 4.5 + 0.3*,††† 
Lung Oedema (Wet:Dry Ratio) 4.3 + 0.0 4.5 + 0.3 4.2 + 0.1 4.3 + 0.1 
Dry Lung:Tibia length (mg/g) 1.7 + 0.1 3.8 + 0.8*** 2.0 + 0.1 1.9 + 0.1†† 
     
 
Supplemental Table 8. Changes in organ weight in α-CGRP analogue (αAnalogue, 50nmol/kg) or 
vehicle (s.c.)-treated sham or AAC-induced cardiac hypertrophy and heart failure mice. Mice 
were treated daily for 5 weeks post surgery. Organs were weighed and normalised to body weight 
(mg/g) or tibia length (mg/mm). Results show mean + SEM (n=6-8). *p<0.05, ***p<0.001 vs respective 
sham-treated; ††p<0.01, †††p<0.001 vs vehicle-treated AAC mice (2-WAY ANOVA + Bonferroni 
post hoc test). 
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Supplemental Figures 
 
Supplemental Figure 1. Effect of local administration α-CGRP analogue (αAnalogue) on vascular 
skin blood flow in naïve mice. Blood flow was monitored using Full-field Laser Perfusion Imager 
(FLPI) in the ear skin of anaesthetised mice (n=4-6) at baseline (5 min) and following intradermal 
injection of αAnalogue (1-100pmol) in the ipsilateral ear and vehicle (0.219M Mannitol, 5% HPCD, 
1.6% ammonium acetate at pH 6.5) in the contralateral ear. Results show mean + SEM for area under 
the curve (AUC) for the 30 min recording. ***p<0.001 vs vehicle-treated ear; #p<0.05 vs αAnalogue 
treated ear (One-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 2. Effect of systemic administration of α-CGRP analogue (αAnalogue) on 
blood pressure in naïve mice. (A) Systolic and (B) diastolic blood pressure was monitored using tail-
cuff plethysmography in trained conscious restrained mice at baseline and 1, 6, 24 and 30h following 
vehicle (0.219M Mannitol, 5% HPCD, 1.6% ammonium acetate at pH 6.5) or αAnalogue administration 
(10, 30, 50 or 100nmol/kg, s.c.). Blood pressure values were obtained for each animal and results show 
mean + SEM for each group of mice (n=7). *p<0.05, **p<0.01 vehicle vs 100nmol/kg αAnalogue 
treatment (Repeated measures 2-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 3. Effect of daily systemic treatment with α-CGRP analogue (αAnalogue, 
50nmol/kg) on cardiovascular haemodynamics in angiotensin II (AngII)-induced hypertension. 
Mice were infused with either AngII (1.1mg/kg/day) or control (saline) with osmotic pumps for 14 days 
and treated daily with vehicle or αAnalogue (50nmol/kg, s.c.). (A) Diastolic blood pressure, (B) mean 
blood pressure, (C) heart rate and (D) activity were measured by radiotelemetry. Results show 
measurement taken every 10 min, expressed as 6h average. Mice experience a 12/12h light/dark cycle, 
with the dark cycle shown in the grey striped area. Arrow represents the start of daily treatment. Results 
show mean + SEM (n=4-7). *p<0.05, **p<0.01, ***p<0.001 vs vehicle-treated saline-infused mice; 
#p<0.05, ##p<0.01, ###p<0.001 for αAnalogue-treated mice AngII-infused vs vehicle-treated AngII-
infused mice (Repeated measures 2-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 4. Daily systemic treatment with the α-CGRP analogue (αAnalogue) 
produces a reproducible reduction in blood pressure in Angiotensin II (AngII)-induced 
hypertension in mice. 6h time course profile of systolic blood pressure following injection of vehicle 
or αAnalogue (50nmol/kg) at Day 1, 3, 7, 10 and 14 in mice infused with saline (A and C) or AngII (B 
and D). Left Panels, Detailed analysis of SBP changes pre-and up to 6h post- αAnalogue or vehicle 
injection in mice infused with saline or AngII. Right Panels, Change (Δ) in SBP at Day 1 and Day 14 
at 1h following injection from baseline (n=4-7). Results show mean + SEM. 
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Supplemental Figure 5. Effects of the α-CGRP analogue (αAnalogue) or vehicle on (A-B) water 
consumption, (C) body weight and (D) food intake in Angiotensin II (AngII)-induced 
hypertension in mice. Baseline measurements of body weight, food and water intake were taken for 7 
days prior to osmotic pump implantation. Mice were administered with osmotic pumps containing 
saline or AngII (1.1 mg/kg/day for 14 day). Measurements were taken daily. Data are mean + S.E.M 
from n=5-7. AUC represents area under the curve results throughout the 14 day recording. Results show 
mean + SEM. *p<0.05, **p<0.01, ***p<0.001 versus vehicle-treated group, #p<0.05, ##p<0.01, 
###p<0.001 versus αAnalogue-treated group (Repeated measures 2-way ANOVA + Bonferroni post 
hoc test for A,C-D and 2-way ANOVA + Bonferroni post hoc test for B). 
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Supplemental Figure 6. Effects of the α-CGRP analogue (αAnalogue) on light-aversion. Mice were 
trained twice daily for 5 days to enable an even distribution to enter the dark covered zone or bright 
light uncovered area (n=6-7). On the test day, time (s) spent in the light (1000 lux) was recorded for 
600s at baseline and 1h following administration of αAnalogue (50nmol/kg, s.c.) or glyceryl trinitrate 
(GTN, 352nmol/kg, i.v.). Results show % time spent in light in mice, mean + SEM (n=6-7). *p<0.05 
vs respective baseline (paired t-tests). 
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Supplemental Figure 7. Effects of the α-CGRP analogue (αAnalogue) on peripheral blood flow in 
mice. Mice were briefly anaesthetised with isoflurane (2%) and blood flow was monitored using Full-
field Laser Perfusion Imager (FLPI) for 5 min. (A) Average blood flow in the ear vasculature at baseline 
(before) and 1h following a single treatment of αAnalogue (50nmol/kg, s.c.) in mice (n=6). Average 
blood flow in the (B) paw, (C) leg and (D) ear of mice at day 14 following daily treatment of vehicle 
or αAnalogue (50nmol/kg, s.c.). Representative FLPI pictures alongside grey/black ‘photo’ showing 
blood flow for vehicle and αAnalogue treatment. Results represent mean + SEM for average 
measurement (flux units) for 5 min recording. p>0.05 ns (two-tailed Student’s t-test). 
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Supplemental Figure 8. Effects of α-CGRP analogue (αAnalogue) on core body temperature and 
activity in mice Core body temperature and activity recordings over 24h at baseline and following 
vehicle or αAnalogue (50nmol/kg, s.c.) treatment in conscious mice (n=5). Results represent average 
1h recording, mean + SEM. Arrow denotes time of treatment and grey area represents night/dark period. 
NS p>0.05 vs vehicle treatment (Repeated measures 2-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 9. Effects of cardiovascular active dose of α-CGRP analogue (αAnalogue) 
on glucose tolerance test in mice. Time course of plasma glucose concentrations (mmol/L) following 
systemic administration of glucose (1g/kg, i.p.) in mice treated daily with (A) vehicle (n=4) and (B) 
αAnalogue (50nmol/kg/day, s.c., n=5) for 14 days. Results show mean + SEM. Arrow denotes treatment 
time of glucose administration. NS p>0.05 vs baseline (Repeated measures 2-way ANOVA + 
Bonferroni post hoc test). 
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Supplemental Figure 10. Effects of α-CGRP analogue (αAnalogue) on vascular eNOS expression 
in mesenteric vessels. Mice were treated daily with the α-CGRP analogue (50nmol/kg, s.c.) or vehicle 
post AngII or saline infusion for 14 days. mRNA expression measured by qRT-PCR (n=4-6) and 
expressed as copy numbers per µl normalised to HPRT, B2M and β-actin. Protein expression normalised 
by GAPDH and shown by immunoblotting (top panel) and densitometry analysis (bottom panel). (A) 
mRNA and (B) protein expression of endothelial nitric oxide synthase (eNOS). Results show mean + 
SEM. ns p>0.05 (2-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 11. Effects of α-CGRP analogue (αAnalogue) on morphological changes in 
the glomeruli in the kidney of Angiotensin II (AngII)-induced hypertension mice. Mice were 
treated daily with the αAnalogue (50nmol/kg, s.c.) or vehicle post AngII or saline infusion for 14 days. 
(A) Representative image showing glomerular mesangial pathology using PAS staining (20µm, scale 
bar). (B) Summarized glomerular matrix expansion by semi-quantification of scores in different groups. 
Results show mean + SEM. *p<0.05 vs vehicle-treated (2-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 12. Effects of α-CGRP analogue (αAnalogue) on plasma noradrenaline (NA) 
level in Angiotensin II(AngII)-induced hypertension mice. Mice were treated daily with the 
αAnalogue (50nmol/kg, s.c.) or vehicle post AngII or saline infusion for 14 days. NA was quantified 
using ELISA (n=6-9). Results show mean + SEM. ns p>0.05 (2-way ANOVA + Bonferroni post hoc 
test). 
  
 
	
31	
 
Supplemental Figure 13. Effects of α-CGRP analogue (αAnalogue) on mRNA expression of 
endothelial-1 (ET-1) level in Angiotensin II(AngII)-induced hypertension mice. Mice were treated 
daily with the αAnalogue (50nmol/kg, s.c.) or vehicle post AngII or saline infusion for 14 days. mRNA 
expression measured by qRT-PCR (n=6-7) for ET-1 in (A) heart and (B) aorta (n=4-11). Results 
expressed as copy numbers per µl normalised to HPRT, B2M and β-actin. Results show mean + SEM. 
ns p>0.05 (2-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 14. Effect of daily treatment with α-CGRP analogue (αAnalogue, 
50nmol/kg) on angiotensin II (AngII)-induced hypertensive mice. Mice were infused with AngII 
(1.1mg/kg/day) osmotic pumps for 14 days and treated with vehicle or αAnalogue (50nmol/kg) on Day 
7-14 (n=4). (A) Mean blood pressure, (B) heart rate and (C) activity were measured by radiotelemetry. 
Results show measurement taken every 10 min, expressed as 6h average. Mice experience a 12/12h 
light/dark cycle, with the dark cycle shown in the grey striped area. Arrow indicates the start of daily 
treatment with vehicle or αAnalogue. *p<0.05, **p<0.01, ***p<0.001 vs vehicle-treated AngII-infused 
mice (Repeated measures 2-way ANOVA + Bonferroni post hoc test). 
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Supplemental Figure 15. Effect of daily treatment with α-CGRP analogue (αAnalogue) on 
abdominal aortic constriction (AAC)-induced cardiac hypertrophy and heart failure in mice. Mice 
were treated with vehicle or αAnalogue (50nmol/kg, s.c.) for 5 weeks post-surgery and cardiac function 
was assessed using echocardiography at week 5. Representative images of cardiac function and 
dimension using M-Mode echocardiography in the parasternal long axis view in mice after sham or 
AAC surgery with or without treatment. 
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Supplemental Figure 16. Effects of the α-CGRP analogue (αAnalogue) or vehicle on (A) body 
weight, (B) food intake, (C) water consumption and (D) light aversion assay in abdominal aortic 
constriction-induced cardiac hypertrophy and heart failure. Mice were treated with vehicle or 
αAnalogue (50nmol/kg, s.c.) for 5 weeks post-surgery. Measurements were taken daily. Data are mean 
+ S.E.M from n=6-8. ns p>0.05 (Repeated measures 2-way ANOVA + Bonferroni post hoc test). 
 
 
 
	
35	
 
Supplemental Figure 17. Changes in blood pressure in vehicle or α-CGRP analogue (αAnalogue)-
treated at 5 weeks following abdominal aorta constriction-induced cardiac hypertrophy and heart 
failure in mice. Blood pressure measurement obtained by carotid artery cannulation in isoflurane-
anaesthetised mice treated daily with the αAnalogue (50nmol/kg, s.c.) or vehicle for 5 weeks (n=7-8). 
Results show mean + SEM. ***p<0.001 vs vehicle treated sham mice (2-way ANOVA + Bonferroni 
post hoc test). 
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Supplemental Figure 18. Daily systemic treatment with α-CGRP analogue (αAnalogue) protects 
against abdominal aorta constriction (AAC)-induced cardiac fibrosis, hypertrophy, inflammation 
and oxidative stress. Following AAC, mice were treated daily for 5 weeks with vehicle or αAnalogue 
(50nmol/kg, s.c.). mRNA expression measured by qRT-PCR (n=6-7) for (A) CTGF, (B) fibronectin, 
(C) collagen type 1 α (COL1A1), (D) collagen type 1 α2 (COL1A2), (E) collagen type 3 α1 (COL3A1), 
(F) collagen type 4 α1 (COL4A1), (G) atrial natriuretic peptide (ANP), (H) brain natriuretic peptide 
(BNP), (I) matrix metalloproteinase-2 (MMP-2), (J) tissue inhibitor of metalloproteinase 2 (TIMP-2), 
(K) sarco-endoplasmic reticulum Ca2+ ATPase-2 (SERCA-2), (L) α-skeletal actin, (M) α-myosin heavy 
chain (α-MHC), (N) β-myosin heavy chain (β-MHC), (O) chemokine RANTES and (P) heme 
oxygenase-1 (HO-1) in heart (n=6-7). Results expressed as copy numbers per µl normalised to HPRT, 
B2M and β-actin. Results show mean + SEM. *p<0.05, **p<0.01, ***p<0.001 vs vehicle-treated sham 
mice; #p<0.05, ##p<0.01, ###p<0.001 vs vehicle-treated AAC mice (2-WAY ANOVA + Bonferroni 
post hoc test).  
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Supplemental Figure 19. Effects of α-CGRP analogue (αAnalogue) on the phosphorylation of p-
38 mitogen-activated protein kinases (MAPK) in the heart of abdominal aortic constriction-
induced cardiac hypertrophy and hear failure in mice. Mice were treated daily with the αAnalogue 
(50nmol/kg, s.c.) or vehicle post-surgery. Protein expression of phosphorylated p-38 was normalised to 
total p-38 (t-p38) and are shown by immunoblotting (top panel) and densitometry analysis (bottom 
panel) in heart tissues (n=6-8). Results show mean + mean. *p<0.05 vs sham-treated, ###p<0.001 vs 
sham-treated (2-WAY ANOVA + Bonferroni post hoc test). 
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